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ABSTRACT
MOLECULAR DETERMINANTS OF RESPONSE TO ANTIANGIOGENIC
THERAPIES IN PRECLINICAL MODELS OF HEAD AND NECK
SQUAMOUS CELL CARCINOMA
Rekha Gyanchandani, PhD
University of Pittsburgh, 2013
BACKGROUND
Head and neck squamous cell carcinoma (HNSCC) is the eighth leading cancer by inci-
dence worldwide. In the past 5 decades there have been signicant advances in surgery and
chemoradiotherapy, but very little improvement in survival rates. Hence, there is a pressing
need to develop new therapeutic strategies in HNSCC. Antiangiogenic therapy represents a
promising strategy in at least a subset of patients. Currently, there are no reliable predictive
and resistance biomarkers to identify those patients most likely to benet. Studies using
relevant preclinical models that identify mechanisms of resistance to antiangiogenic agents
will help meet these challenges.
PRINCIPLE FINDINGS
In this dissertation, we established preclinical models of intrinsic and acquired resistance to
anti-VEGF antibody bevacizumab and identied potential biomarkers of drug response.
To characterize mechanisms of intrinsic resistance, we evaluated the angiogenic prole
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of HNSCC cells from sensitive and resistant models using antibody array. We showed that
resistant cells expressed higher levels of proangiogenic factors including interleukin-8 (IL-8).
We identied PI3K and IL-1 signaling as the molecular basis for overexpression of IL-8.
Downregulation of IL-8 resulted in sensitization of resistant tumors to bevacizumab. Over-
expression of IL-8 in sensitive tumors conferred resistance to bevacizumab. Serum analysis
of HNSCC patients treated with a bevacizumab-containing regime indicated high baseline
IL-8 levels in a subset of patients refractory to treatment but not in responders.
In a novel xenograft model of acquired resistance, human-specic microarray analy-
sis revealed upregulation of angiogenesis-related genes including broblast growth factor-2
(FGF2), broblast growth factor receptor-3 (FGFR3), phospholipase C gamma-2 (PLCg2),
frizzled receptor-4 (FZD4), chemokine [C-X3-C motif] ligand-1 (CX3CL1), and chemokine
[C-C motif] ligand-5 (CCL5). Upstream genes PLCg2, FZD4, CX3CL1, and CCL5 regulated
increased expression of FGF2 via increased extracellular signal-regulated kinase (ERK) sig-
naling. Co-targeting VEGF and FGFR sensitized resistant tumors to bevacizumab.
CONCLUSIONS AND SIGNIFICANCE
Our work has identied two distinct molecular mechanisms of resistance to bevacizumab in
preclinical HNSCC models. IL-8 signaling mediated intrinsic resistance while upregulation of
FGF signaling in response to anti-VEGF therapy contributed to acquired resistance. Above
ndings provide a mechanistic rationale for co-targeting these pathways in future clinical
trials to enhance therapeutic ecacy.
Keywords: Angiogenesis, Acquired resistance, Bevacizumab, Biomarker, FGF, HNSCC,
Intrinsic resistance, IL-8.
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1.0 INTRODUCTION
1.1 HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Head and neck cancers include cancers of the oral cavity, pharynx, larynx, and other mucosal
surfaces of the upper aerodigestive tract. The most common type of head and neck cancer
is the squamous cell carcinoma (HNSCC), originating from the mucosal lining (epithelium)
of these regions. HNSCC is the eighth most common malignancy and a major cause of
cancer morbidity and mortality worldwide [1]. Globally, an estimated 650; 000 new cases
are reported annually. In the United States, approximately 40; 000 new cases are diagnosed
in both the sexes each year. Currently, the average ve-year survival rate for this disease
is 62%. This rate is highly dependent on the stage at diagnosis; with early stage diag-
noses having an 82% ve-year survival rate and advanced stages having only a 35% survival
rate [2]. Approximately two-thirds of HNSCC patients present with advanced stage disease.
Initial presentation with distant metastasis occurs in about 16% of all patients. However,
recurrence of disease either in local or distant sites occurs in close to 47% of patients. These
patients have a dismal prognosis with a median survival of only 6-9 months.
The major etiological factors for HNSCC include tobacco use and alcohol consumption.
The substances present in tobacco such as nicotine and polycyclic hydrocarbons have been
shown to exert direct carcinogenic eects [3]. In fact, mutations in the tumor suppressor gene,
TP53, have been shown to correlate with substantial exposure to alcohol and tobacco [4].
HNSCC is also increased by tobacco chewing as seen in certain parts of Asia where chewing
of betel quid is prevalent [5]. In addition, viruses such as Epstein-Barr virus (EBV) and
HPV have been linked with head and neck cancer. EBV is associated with nasopharyngeal
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carcinoma (NPC) [6, 7]. However, HPV is mostly associated with oropharyngeal carcinoma
specically those of the lingual and palatine tonsils [8]. The increasing trend of HPV-linked
oropharyngeal carcinoma is predominant in patients under the age of forty-ve due to the
practice of oral sex, and the increasing number of sexual partners [9].
Head and neck tumorigenesis is a multistep process driven by specic genetic alterations
caused by continuous exposure to carcinogens. These molecular changes involve the activa-
tion of oncogenes as well as the inactivation of tumor suppressor genes [10,11]. This results in
oncogenic transformation and concomitant phenotypic changes in the tumor cells that allow
them to survive and proliferate forming a clinically detectable tumor mass. Some of these
important phenotypic changes include evasion of apoptosis, tissue invasion and metastasis,
as well as acquiring the ability to induce angiogenesis.
1.2 ANGIOGENESIS AND HNSCC
Angiogenesis, the sprouting of new blood vessels from a pre-existing network, is of critical
importance during tumor formation and also in a number of normal physiologic processes
including embryonic development [12], wound healing [13] and reproduction [14]. Like nor-
mal tissues, tumors require an adequate supply of oxygen and nutrients for their growth and
survival. Initially, solid tumors arise as avascular masses that can derive metabolites from
pre-existing vasculature by simple passive diusion. But, in order to grow beyond the size
of 2 to 3mm in diameter, tumors require inducing their own blood supply [15]. Available
evidence suggests that the so called \angiogenic switch" (induction of tumor vasculature) is
triggered in response to an imbalance between the relative amounts of molecules that stim-
ulate (proangiogenic) and inhibit (antiangiogenic) angiogenesis [16,17].
Like all solid tumors, HNSCC relies upon angiogenesis in order to continue to proliferate
and metastasize [18, 19]. Normal keratinocytes and HNSCC cells are known to produce a
variety of angiogenic factors including IL-8, vascular endothelial growth factor (VEGF), pla-
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cental growth factor (PlGF) and FGF. IL-8 expression has been shown to be associated with
tumor cells in HNSCC samples using immunohistochemistry [20]. In addition, in the closely
related bronchogenic carcinomas, IL-8 has been the primary mediator of angiogenesis found
in fresh tumor homogenates [21]. VEGF on the other hand, is considered as the prototyp-
ical proangiogenic factor whose biological activity is primarily associated with endothelial
cells [22]. These proangiogenic proteins can bind to their corresponding receptors located
on the surface of endothelial cells and activate signaling cascades that lead to endothelial
cell proliferation, directional migration and vessel formation. There can also be an indirect
induction of angiogenesis by interaction of tumor cells with their surrounding stroma. HN-
SCC cells have been shown to attract monocytes and activate them to secrete angiogenic
factors [23]. Also, macrophages are known to produce cytokines that stimulate the tumor
cells (via paracrine signaling) to produce increased levels of IL-8 and VEGF.
1.2.1 Vascular Endothelial Growth Factor (VEGF)
An extensive body of evidence indicates that blockage of proangiogenic factor signaling can
result in inhibition of tumor growth [24{29]. Among the validated antiangiogenic strategies,
perturbation of VEGF signaling has gained primary focus. VEGF-A or commonly VEGF is
the most important member of the VEGF family of growth factors consisting of VEGF-A,
PlGF, VEGF-B, VEGF-C and VEGF-D. Multiple isoforms of human VEGF-A are gener-
ated by alternative exon splicing of a single gene [30]. VEGF121, VEGF165, VEGF189 and
VEGF206 are the major VEGF-A isoforms, with less frequent splice variants VEGF145,
VEGF183 [31].
VEGF-A mediates its cellular responses by binding to tyrosine kinase receptors (the
VEGFRs) on the surface of endothelial cells, resulting in receptor dimerization and acti-
vation through transphosphorylation (Figure 1.1) [32]. The VEGFRs have an extracellular
region consisting of seven immunoglobulin-like domains, a single transmembrane spanning re-
gion, and an intracellular kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2
(KDR/Flk-1). VEGFR-2 appears to be the principal receptor of VEGF-A supporting its
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proliferative functions [31, 33]. Tyr1175 (Y1175) and Tyr1214 (Y1214) are the two major
autophosphorylation sites in VEGFR-2. PLC-g binds to Y1175, leading to the phosphory-
lation and activation of this protein. Y1214 appears to be required to trigger the sequential
activation of Cdc42 and p38 MAPK. Many proteins are activated by VEGFR-2 through an
unknown mechanism, including FAK, PI3K and Src.The activation of downstream signal
transduction molecules leads to several dierent endothelial cell functions such as migration,
vascular permeability, survival and proliferation. VEGF-C and VEGF-D, but not VEGF-A,
are ligands for a third receptor (VEGFR-3), which mediate lymphangiogenesis.
1.2.2 Role of VEGF in HNSCC
VEGF-A is widely expressed in most human cancers [34{36] including head and neck cancers
and higher levels of expression have been associated with increased tumor vascularity [37],
metastasis [38] and poor prognosis [39]. The study by Sauter et. al. provided the rst di-
rect evidence of a correlation between VEGF expression and increased microvessel density
in HNSCC compared to normal tissues [37]. In another study involving 29 specimens from
human nasopharyngeal carcinoma, a signicant relationship between microvessel density and
high VEGF expression was determined, suggesting the importance of VEGF-dependent an-
giogenesis in the occurrence of lymph node metastasis [38]. Further, the study by Mineta et.
al. showed that high VEGF expressors were associated with the progression of lymph node
spread, which correlated with poor disease-free survival [39].
Expression of VEGF is regulated by a variety of stimuli such as hypoxia, growth factors,
and p53 mutation, etc. Rapid tumor cell growth creates intracellular hypoxia, which initi-
ates a series of cell signaling events that promote angiogenesis. VEGF is transcriptionally
regulated by hypoxia-inducible factor (HIF-1), which is in turn negatively regulated by
the von Hippel-Lindau (VHL) tumor suppressor protein during normoxia [40, 41]. Apart
from the hypoxia triggered up-regulation of VEGF, a number of growth factors including
epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), and platelet-derived
growth factor (PDGF), up-regulate VEGF mRNA expression, suggesting that paracrine or
4
Figure 1.1: Binding specicity of various vascular endothelial growth factor (VEGF)
family members and VEGFR signaling. The VEGF family consists of seven ligands derived
from distinct genes (VEGF-A, -B, -C, -D and -E, placenta growth factor [PlGF] -1 and -2). In
addition, specic family members, such as VEGF-A, may be expressed as isoforms due to mRNA
alternative splicing. VEGF family members and isoforms have specic binding anities to VEGF
receptor (VEGFR) -1, VEGFR-2 and VEGFR-3 tyrosine kinase receptors as shown. In addition,
neuropilin (NRP) -1 and NRP-2 are co-receptors for specic isoforms of VEGF family members and
increase binding anity of these ligands to their respective receptors. The activation of downstream
signal transduction molecules leads to several dierent endothelial cell functions such as migration,
vascular permeability, survival and proliferation [32].
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autocrine release of such factors can contribute in regulating VEGF release in the microen-
vironment [42]. In addition, wild type p53 down-regulates VEGF, whereas the p53 mutants
have no eect on the VEGF promoter activity [43]. A study by Riedel et. al. revealed
that the number of p53 mutations was signicantly higher in the VEGF-positive HNSCC
than the VEGF-negative HNSCC, indicating the important role of p53 in the regulation of
VEGF-dependent angiogenesis in HNSCC [44].
1.2.3 VEGF-targeted Therapeutics in HNSCC
Several therapeutic strategies have been developed to inhibit VEGF-induced angiogenesis
(Figure 1.2) [45]. They involve neutralization of the biological activity of VEGF protein using
monoclonal antibodies such as bevacizumab (Avastin, Genentech, Inc.) (Figure 1.3A) [46,47]
or inhibition of the tyrosine kinases stimulated by VEGF using small molecules (tyrosine
kinase inhibitors or TKIs) such as sunitinib (Sutent, Pzer, Inc.) (Figure 1.3B) [48] and
sorafenib (Nexavar, Onyx/Bayer) (Figure 1.3C) [49]. Currently, these agents have been
FDA-approved for the treatment of metastatic neoplasms such as colon, lung, and renal
cancers (Table 1.1). However, in head and neck cancers, they are still under active clinical
investigation [50].
1.2.3.1 Monoclonal Antibodies Bevacizumab is a fully humanized monoclonal anti-
body against VEGF. It is the rst and by far the most successful antiangiogenic drug that
has been FDA approved for use in metastatic colorectal cancer, non-small cell lung cancer,
and renal cell carcinoma [51]. Bevacizumab is also approved for use as second-line agent in
glioblastoma multiforme.
Preclinical studies have reported that bevacizumab can enhance the therapeutic ecacy
of established therapy for HNSCC such as chemotherapy, radiation therapy, and epidermal
growth factor receptor (EGFR) directed therapy including cetuximab [52{54]. Although
bevacizumab is currently being evaluated in phase III clinical trials (NCT00588770), results
from phase II clinical trials indicate that bevacizumab shows little activity as single agent
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in HNSCC. The single-agent response rate is less than 10%, and even in patients who do
respond, the duration of response is typically less than 3 months [55, 56]. VEGF has been
shown to be a downstream target of EGFR signaling cascade and VEGF up-regulation
through EGFR activation has been correlated with resistance to EGFR-targeting agents [57].
Using this rationale, a phase I/II study of bevacizumab in combination with elotinib was
conducted by Vokes et. al. involving 51 patients with recurrent or metastatic (R/M) HNSCC
[55]. An overall response rate of about 15% was seen, which was signicantly higher than that
with either agent alone. However, median survival was similar to that with chemotherapy
alone with less toxicity. Two (4%) of the patients had complete response, ve (10%) had
partial response, twenty-six (56%) had stable disease and fteen (30%) had progressive
disease. Interim analysis of an on-going phase II study of pemetrexed and bevacizumab
in patients with R/M HNSCC at the University of Pittsburgh [56], showed that two (18%)
of the patients had complete response, three (27%) had partial response, six (54%) had stable
disease and none (0%) had progressive disease.
1.2.3.2 Small Molecule Inhibitors Sunitinib, an oral multikinase inhibitor, which is
approved for metastatic renal cell carcinoma and gastrointestinal stromal tumors, targets
VEGFRs, PDGFR, RET and c-KIT kinases. A Phase II study conducted to evaluate the
tolerability and ecacy of sunitinib in metastatic and/or recurrent HNSCC patients, also
concluded that sunitinib had low single agent activity [58]. Sorafenib, another multikinase
inhibitor targeting VEGFRs, PDGFR- and Raf-1, has shown anti-cancer activity in pre-
clinical studies [59] and is approved for unresectable hepatocellular carcinoma and renal cell
carcinoma. Phase II trials in R/M HNSCC patients with single agent sorafenib showed stable
disease in ten (38%) patients and a median overall survival of 8 months [60].
1.2.4 Resistance to VEGF-targeted Therapeutics in HNSCC
Clinical trials with VEGF-targeted agents in HNSCC and several other cancers indicate that
the therapeutic ecacy of these drugs is limited to date. Majority of the patients demon-
strate an initial clinical response to the treatment but eventually exhibit progressive disease
(acquired resistance). In addition, some patients show pre-existing indierence to angiogene-
7
Figure 1.2: Current clinical agents targeting VEGF pathway and their mechanisms
of inhibition. A, bevacizumab is a humanized monoclonal antibody directed at VEGF. B, IMC-
1121B is a humanized monoclonal antibody targeting the VEGFR-2, thereby inhibiting ligand
binding and activation of the receptor. C, TKIs are orally available agents that compete with ATP
in the intracellular tyrosine kinase domain of the receptor. [45, 61].
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DRUG CATEGORY DESCRIPTION APPROVED
INDICATIONS
1 Bevacizumab/
Avastin
Humanized
Monoclonal
Antibody
Binds biologically
active form of VEGF
 Metastatic Renal Cell
Cancer (RCC)
 Metastatic Colorectal
Cancer (CRC)
 Recurrent or Metastatic
Non-Small Cell Lung
Cancer (NSCLC)
2 Sorafenib/
Nexavar
Small
molecule
TKI
Inhibits VEGFR-1,
VEGFR-2, VEGFR-3,
PDGFR-, & Raf-1.
 Advanced Renal Cell
Carcinoma
 Advanced Hepatocellu-
lar Carcinoma (HCC)
3 Sunitinib/
Sutent
Small
molecule
TKI
Inhibits VEGFR-1,
VEGFR-2, VEGFR-3,
PDGFR-, & RET.
 Advanced Renal Cell
Carcinoma
 Gastrointestinal Stro-
mal Tumor (GIST)
Table 1.1: FDA approved antiangiogenic drugs.
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(A) (B)
(C)
Figure 1.3: Structures of VEGF inhibitors. (A) Bevacizumab, (B) Sunitinib, (C) Sorafenib.
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sis inhibition (intrinsic resistance), such that tumor progression continues unabated. These
incomplete drug responses are likely due to the complexity of signaling networks that the
tumor cells can exploit in the setting of VEGF blockade. Currently, there are no reports
that elucidate the molecular mechanisms of resistance to anti-VEGF therapy in HNSCC.
However, some potential mechanisms have been proposed in other cancers to account for the
resistance of tumors to antiangiogenic therapy that are briey discussed below [33,62{66].
1.2.4.1 Intrinsic Resistance to VEGF-targeted Therapeutics Although VEGF is
the predominant angiogenic factor in human tumors, there is a pre-existing multiplicity of
redundant growth factors produced by both tumor cells as well as the stroma that can com-
pensate for the suppression of VEGF-mediated angiogenesis.
A recent study by Huang et. al. showed that IL-8 expression was elevated in human renal
cell carcinoma (RCC) tumors with intrinsic resistance to sunitinib therapy [67]. Further,
neutralization of IL-8 activity in RCC xenograft models resensitized tumors to sunitinib
treatment. In murine tumor models, inltrating myeloid cells produced proangiogenic factors
including Bv8 and tumor cells secreted HGF, which mediated intrinsic resistance to anti-
VEGF antibody and sunitinib respectively [68,69].
1.2.4.2 Acquired Resistance to VEGF-targeted Therapeutics Unlike intrinsic re-
sistance, tumors can activate and/or upregulate other angiogenic factors in response to
anti-VEGF inhibitors. By acquiring alternative ways to sustain growth and survival, tu-
mors can adapt to the eects of angiogenic inhibitors thereby displaying acquired resistance.
Antiangiogenic therapies reduce and normalize tumor vasculature but increase intratumor
hypoxia [70]. This can result in HIF-1-mediated expression of several genes involved in
angiogenesis.
In a xenograft murine model of human Wilms' tumor, vascular remodeling was seen in
tumors that recurred during chronic suppression of angiogenesis [71]. In addition, remodeled
vessels were marked by increased expression of ephrinB2 and platelet-derived growth factor-
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B (PDGF-). In a xenograft model of pancreatic-islet tumors, Casanovas et. al. showed that
treatment with an anti-VEGFR2 monoclonal antibody was associated with a decrease in
microvessel density after ten days of therapy [72]. However, an angiogenic revascularization
was observed at four weeks that was associated with an increased expression of other proan-
giogenic factors including members of the FGF family. In addition, antiangiogenic therapy
showed in antitumor eects in mouse models but concomitantly resulted in increased local
invasion and distant metastasis [73]. In a separate study, levels of plasmatic PlGF have
been shown to be increased following anti-VEGF therapy and seem to be implicated in
acquired resistance [74]. In a preclinical study, antibody to PlGF resensitized xenografts
to anti-VEGFR2 therapy by preventing inltration of angiogenic macrophages [75]. Up-
regulated stromal EGFR and FGFR have been described in bevacizumab-resistant NSCLC
xenografts [76]. Higher expression of proinammatory factors resulted in increased aggres-
siveness of bevacizumab-resistant pancreatic tumors [77]. In a mouse model of endometrial
cancer, bevacizumab treatment over a 5-week period retards tumor growth in mice but is
accompanied by up-regulation of certain proto-oncogenes including c-Jun [78]. A recent
study in glioma xenografts models of acquired sunitinib resistance presented with activation
of prosurvival pathways including upregulation of PLCg-1 signaling [79].
1.3 RATIONALE, HYPOTHESIS AND SPECIFIC AIMS
Preclinical and clinical studies in HNSCC have revealed bevacizumab to be a promising drug
for antiangiogenic therapy in at least a subset of patients. Currently, there are no reliable
biomarkers to identify those patients most likely to benet. Therapeutic ecacy of this
drug can be further improved if the molecular determinants of resistance to bevacizumab
are known. As discussed above, studies from other cancers indicate that tumors can rely on
multiple escape mechanisms using a variety of angiogenic proteins secreted by both tumor
cells and stromal cells. These molecular mechanisms of resistance are completely unknown in
HNSCC. Also, among the several potential mechanisms known from other cancers, selection
of one critical mediator of resistance for cotargeting with VEGF remains a daunting task. To
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address these issues, it is necessary to carry out studies that will address the mechanisms of
resistance to anti-VEGF therapy in HNSCC. Further, preclinical models that test combina-
torial therapies along with VEGF inhibitors will be integral in selection of a suitable cotarget.
We therefore propose to establish HNSCC xenograft models of bevacizumab resistance
to mimic the resistance seen in the clinical setting. We hypothesize that altered sig-
naling through angiogenic factors other than VEGF (such as IL-8, IL-1, and
FGF), contribute to anti-VEGF therapy resistance in HNSCC. We will explore this
hypothesis using preclinical models in the three specic aims outlined below. Completion of
these studies will elucidate mechanisms of anti-VEGF therapy resistance in HNSCC thus fa-
cilitating the design of more eective anti-cancer treatments by employing novel combination
therapies.
1. To establish and characterize preclinical HNSCC models of intrinsic and ac-
quired models of resistance to VEGF-targeted agents.
These studies will test the hypothesis that HNSCC cell lines display dierential sensitiv-
ity to anti-VEGF agents in vivo, and that these cell lines can serve as the basis for models
of intrinsic resistance to anti-VEGF therapy. We further hypothesize that chronic treat-
ment of the sensitive cell lines with anti-VEGF therapy will result in evasive resistance,
resulting in the establishment of models of acquired resistance to anti-VEGF therapy.
2. To identify signaling molecules that contribute to anti-VEGF refractoriness
in the preclinical HNSCC models.
These studies will test the hypothesis that altered signaling through angiogenic factors
other than VEGF (such as IL-8, IL-1 and FGF) provides a mechanism of escape from
VEGF blockade in the preclinical HNSCC models that are established in aim 1.
3. To develop novel co-targeting strategies for overcoming anti-VEGF resistance
in the preclinical HNSCC models.
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These studies will test the hypothesis that co-targeting molecules responsible for escape
of VEGF blockade (such as IL-8, IL-1 and FGF) in conjunction with VEGF will improve
therapeutic ecacy of anti-VEGF agents in preclinical HNSCC models.
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2.0 HNSCC XENOGRAFT MODELS OF INTRINSIC RESISTANCE TO
BEVACIZUMAB
2.1 INTRODUCTION
Promising results from preclinical studies in HNSCC, have reported that bevacizumab can
enhance the therapeutic ecacy of established treatment modalities such as chemotherapy,
radiation therapy, and epidermal growth factor receptor (EGFR) targeted therapy including
cetuximab [52{54]. Clinical data also suggests that targeting the vasculature in a subset of
patients will represent an eective therapeutic strategy [55, 56, 80{82]. However, currently
there are no validated biomarkers that can be used reliably to determine which patients will
respond to bevacizumab therapy. The identication of such biomarkers will enable design
of novel combinatorial approaches to specically target the subgroup of patients who are
expected to be resistant to this antiangiogenic agent. A fundamental understanding of the
molecular mechanisms of resistance is therefore a necessary prerequisite to help meet these
goals.
Here, we investigated the mechanisms of intrinsic resistance to bevacizumab in preclinical
HNSCC models. A panel of head and neck cancer cell lines were screened in vivo for their
dierential response to bevacizumab treatment. The HNSCC cell lines that displayed low
sensitivity to bevacizumab served as a model of intrinsic resistance and the cell lines that
showed high sensitivity to bevacizumab were used as a non-isogenic model for comparison.
In order to characterize the escape mechanisms underlying intrinsic resistance and identify
potential biomarkers of drug response, we evaluated the angiogenic prole of HNSCC cells
from sensitive and resistant cell lines using antibody array. We further examined the dif-
ferentially expressed proteins both in vitro and in vivo for their involvement in conferring
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intrinsic resistance, using loss- and gain-of-function approaches.
2.2 MATERIALS AND METHODS
2.2.1 Cells and Reagents
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza Inc. (San
Jose, CA) and were maintained in EBM2 media supplemented with growth factors. Tu138
and HN5 cells were maintained in DMEM/F12 with 10% FBS. FaDu cells were maintained in
DMEM with 10% FBS, 1% non-essential amino acids and 1% sodium pyruvate. SCC61 cells
were maintained in DMEM with 20% FBS, 1% non-essential amino acids, 1% sodium pyru-
vate and 0:4ug/ml hydrocortisone. All four previously characterized cell lines were validated
by genotyping using short tandem repeat analysis [83]. Bevacizumab (Avastin, Genentech
Inc., South San Francisco, CA) was purchased from the University of Pittsburgh Pharmacy
with stock concentration of 25mg/ml and diluted as recommended in the instructions. NVP-
BEZ235 was purchased from Selleck Chemicals (Houston, TX). Recombinant hVEGF, hIL-8
and hEGF were purchased from R&D Systems (Minneapolis, MN).
2.2.2 Animal studies
Five- to six-week-old female athymic nude-Foxn1nu mice were purchased from Harlan Labo-
ratories (Indianapolis, IN) and were maintained under guidelines provided by the University
of Pittsburgh Institutional Animal Care and Use Committee (IACUC). For the dierential
sensitivity screen, tumor cells (3  106 cells/mouse) were suspended in complete medium
and subcutaneously implanted into the dorsal ank of mice. After formation of palpable
tumors within 2 weeks of inoculation, the mice were randomized to receive either vehicle
(control) or bevacizumab (4mg/kg) and administered biweekly via intraperitoneal injec-
tion for a period of 29 days. Tumor volumes were assessed using caliper measurements
as 3:14=6  length  width2. Mean tumor values were compared using students' t-test.
P-value < 0:05 was considered signicant.
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For the combination treatment experiments, Fadu-shIL8, SCC61-shIL8 and Tu138-IL8
overexpressing cells along with the respective control cells were used to generate xenografts
and tumor growth was assessed in the absence or presence of bevacizumab (4mg/kg). Ten
mice were subcutaneously implanted with FaDu-control or -shIL8 cell lines (3106 cells/mouse)
while 20 mice were subcutaneously implanted with SCC61-control or -shIL8 cell lines (2106
cells/mouse). For Tu138-control or -IL8 overexpressing cell lines (3  106 cells/mouse) ten
mice each were used. All in vivo studies were carried out for a period of 29 days, except for
the Tu138 IL8 overexpression study, which was ended at day 18 due to tumor ulceration.
2.2.3 Antibody array
Nineteen angiogenesis-related proteins were measured in tumor cell-conditioned medium us-
ing antibody array (Panomics/ Aymetrix Inc., Santa Clara, CA) according to the man-
ufacturer's instructions. The growth factors that we examined were as follows: TIMP-1,
TIMP-2, IP-10, IL-12, IFN-g, TGF-, TNF-, FGF-a, FGF-b, PlGF, IL-8, IL-6, IL-1, IL-
1, VEGF, Leptin, HGF, G-CSF and Ang. Biotin-conjugated antibodies spotted on every
membrane served as positive controls. For conditioned media, Tu138 and SCC61 cell lines
were plated at a density of 1  106 cells/10cm dish. Culture medium was replaced with
serum-free medium and collected after 48 hours.
2.2.4 ELISA
HNSCC cell lines were plated at a density of 1  105 cells per 6-well plate. Cell culture
supernatant was collected after 24 hours and centrifuged at 1200rpm for 5 min. IL-8, IL-1,
VEGF, FGF-a and TNF- were measured from the supernatant using individual ELISA kits
(R&D Systems, Inc. Minneapolis, MN) according to the manufacturer's protocol.
IL-8 was also measured in patient sera using ELISA. Baseline (pretreatment) serum
samples from thirty-two patients were run in duplicates and the mean value was used for
analysis.
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2.2.5 Cell Proliferation
HUVECs were plated in 48-well plates (in triplicates) at a density of 3 104 cells/well. The
following day complete EBM-2 was replaced with medium (4% FBS containing EBM-2) alone
or medium containing VEGF, IL-8, or bevacizumab. Complete EBM-2 medium was used
as a positive control. Standard MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay was performed at the start of the experiment and after 24 hrs to obtain day
zero and day one reading for dierent treatment groups. 200l of MTT solution was added
to each well, and the plates were incubated at 37 C for 2 hr in a 5% CO2 incubator. To
dissolve the formazan crystals, 150l of Dimethyl sulfoxide (DMSO) was added to each well
and mixed by pipetting. The optical density (OD) of each well was measured at 570nm
with an enzyme-linked immunosorbent assay (ELISA) microtiter plate reader, model 3550
(Bio-Rad Laboratories, Hercules, CA).
2.2.6 Transwell migration
5  103 HUVECs were plated in the upper chamber of 8-micron transwell lters (BD Bio-
sciences, Bedford, MA) with serum-free EBM-2 medium in duplicate. In the lower chamber
of transwell lters, 250l of medium (4% FBS containing EBM-2) alone or medium con-
taining VEGF, IL-8, or bevacizumab was added and the cells were allowed to migrate for
24 hrs in 5% CO2 at 37
C. At the end of the assay, the lter side of the upper chamber
was cleansed with a cotton swab and stained with Fisher Hema 3 system (Fisher Scientic,
Pittsburgh, PA) and then rinsed in water. The number of cells that migrated across the
lters was counted under 200 magnication.
2.2.7 Capillary-tube formation
1105 HUVECs were plated on 24-well plates precoated with type I collagen gels (3mg/ml)
(PureCol, Advanced BioMatrix, Inc., San Diego, CA) in medium alone (1% FBS containing
EBM-2) or medium containing VEGF, IL-8, or bevacizumab. Complete EBM-2 medium was
used as a positive control. After 24 hrs of incubation, plates were examined for capillary
tube formation by microscopy and photographed. Each assay was done in triplicate and
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each experiment was repeated four times. Quantitative analysis of capillary tube formation
was performed by counting the number of tubes (dened as multicellular cord-like structures
between two multicellular nodes) in two-dimensional brighteld microscope images.
2.2.8 Western
HUVECs were plated at a density of 1:5 106 cells /10cm dish. The following day complete
EBM-2 was replaced with serum-free EBM-2 medium alone or medium containing VEGF,
IL-8, or bevacizumab. After 24 hrs of incubation, whole cell lysates were prepared using
25mM Tris-HCl (pH 7:6), 150mM NaCl, 0:5% Sodium dodecylsulphate, 0:1% SDS and pro-
tease inhibitor cocktail set (Roche). Protein content was quantied using Bradford assay.
40g of total protein was separated by 8% SDS-PAGE and blotted onto PVDF mem-
branes (Amersham Biosciences). The membranes were blocked for 1 hr using 5% milk in
PBS containing 0:1% Tween-20 and then incubated with 1:1000 diluted rabbit anti-pAKT
(Ser473) antibody (Cell Signaling Technology, Inc. Danvers, MA) at 40 C overnight. Sec-
ondary antibody incubations were carried out using 1:2000 diluted goat anti-rabbit IgG
(H+L)-HRP conjugate antibody (Bio-Rad Laboratories, Hercules, CA). Reactive bands were
detected by chemiluminiscence using ECL plus western blotting detection kit (Amersham
Biosciences) and analyzed by densitometry using ImageJ (NIH, Bethesda, Maryland, USA).
The membranes were also probed with 1:1000 diluted rabbit anti-AKT and anti--Actin
polyclonal antibody (Cell Signaling Technology, Inc. Danvers, MA) and 1:2000 diluted goat
anti- rabbit IgG (H+L)-HRP conjugate antibody (Bio-Rad Laboratories, Hercules, CA) as a
control for equal gel loading. Similarly, immunoblots were performed for SCC61 cells treated
with DMSO, EGF or NVP-BEZ235 using the following antibodies; EGFR, pEGFR (Tyr992)
(Cell Signaling Technology Inc., Danvers, MA) and IL-8 (Abcam, Cambridge, MA).
2.2.9 Plasmids
Lentiviral shRNA was used to knockdown IL-8 expression in bevacizumab-resistant (FaDu
and SCC61) cells. Lentiviral particles were provided by Dr. Robert W. Sobol (University of
Pittsburgh Cancer Institute (UPCI) Lentiviral Core Facility). HNSCC cells were incubated
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with lentivirus particles and polybrene 8g/mL for 16 hours and then washed with media.
Cells were selected with 0:5g/ml puromycin for two weeks before conrmation of knock-
down using ELISA. Five dierent oligonucleotide sequences of IL-8 shRNA were tested for
optimal knockdown of protein and the following sequences were selected.
CCGGCAAGAGAATATCCGAACTTTACTCGAGTAAAGTTCGGATATTCTCTTGTTTTTG
CCGGCAAGGAGTGCTAAAGAACTTACTCGAGTAAGTTCTTTAGCACTCCTTGTTTTTG
For overexpressing IL-8, bevacizumab-sensitive Tu138 cells were transfected with pSELECT-
PURO-MCS or pSELECT-PURO-IL-8 expression plasmids (InvivoGen, San Diego, Cali-
fornia) followed by selection with puromycin (1:5g/ml) and ELISA to validate increased
expression of IL-8 protein.
2.2.10 Immunohistochemistry and Immunouorescence
Frozen tumor sections (8-10 mm) from each group were mounted on positively charged
Superfrost slides (Fischer Scientic, Houston, TX). The slides were washed in Tris Buer
Saline/ Tween 20 and incubated in endogenous peroxidase and protein blocking solution
Rodent block (BioCare, Concord, CA). The samples were then incubated with rat anti-
mouse CD31 antibody (BD Biosciences Pharmingen, San Jose, CA). After washing, the
slides were incubated in rat Probe followed by Rat polymer (Biocare Rat on Mouse Kit).
The slides were then incubated in chromogen DAB Quanto (Thermo Scientic/Lab Vision,
Kalamazoo, MI). Slides were stained in Mayer's Hematoxilin and coversliped with Permount.
Frozen tumor sections were xed and blocked as above, excluding the endogenous per-
oxidase step. The slides were incubated with rat anti-mouse CD31 monoclonal antibody,
washed with PBS, blocked with protein block and incubated with Texas Red-X goat anti-
rat IgG antibody (Invitrogen, Grand Island, NY). To stain for terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL), a commercially available Apopto-
sis Detection kit (Promega, Madison, WI) was used. Slides were washed with PBS and
mounted using Vectashield Mounting Medium with DAPI (Vector laboratories, Burlingame,
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CA). Immunouorescence microscopy was carried out using an Olympus IX81-DSU Spinning
Disk Confocal Microscope. Images were captured using a Hamamatsu ORCA II ER camera
(Hamamatsu Corp.) and 3i Slidebook 5:0 software.
For quantication of CD31 expression, vessels completely stained with anti-CD31 anti-
bodies were counted in random 0:04  mm2 elds at using a 20 objective. Quantication
of CD31/TUNEL staining was done as the average percentage of apoptotic endothelial cells
in 10 random 0:01 mm2 elds using a 40 objective.
2.2.11 Statistical Analysis
Data are expressed as mean  S.E.M. Student's t test was used for all statistical analyses
except for the serum IL-8 study where P-values were derived from a two-tailed probability
generated using Mann Whitney test. Signicance tests were performed with a two-sided
signicance level of 0:05.
2.3 RESULTS
2.3.1 Dierential sensitivity of HNSCC xenografts to bevacizumab
We rst sought to investigate the ecacy of bevacizumab in dierent preclinical HNSCC
models. Tu138 (Figure 2.1A) and HN5 (Figure 2.1B) tumors were sensitive to bevacizumab
resulting in 88% and 75% growth inhibition compared to the respective vehicle controls.
FaDu (Figure 2.1C) tumors showed an intermediate response with 58% growth inhibition
while SCC61 (Figure 2.1D) tumors exhibited the least response (non-signicant 41% growth
inhibition). Overall, HNSCC xenografts displayed a dierential response to bevacizumab
where Tu138 tumors were most sensitive and SCC61 tumors were least sensitive. Given
this nding, we initially focused our eorts on identifying the mechanisms of resistance to
anti-VEGF treatment by comparing the Tu138 and SCC61 xenograft models.
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(A) (B)
(C) (D)
Figure 2.1: Dierential sensitivity of HNSCC xenografts to bevacizumab. Athymic
nude mice (n=8) were subcutaneously implanted with HNSCC cell lines including Tu138 (A),
HN5 (B), FaDu (C) & SCC61 (D). After tumor formation, mice were grouped and given saline
or bevacizumab. Tumor volumes were assessed using caliper measurements and compared using
student's t-test. P-value < 0:05 was considered signicant (?). Tu138, 88% inhibition, P = 0:0007;
HN5, 75% inhibition, P = 0:014; Fadu, 58% inhibition, P = 0:023; & SCC61, 41% inhibition,
P = 0:2613.
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2.3.2 Resistant HNSCC cells secrete higher levels of several angiogenic factors
including IL-8
We assayed for dierences in secreted angiogenic factors between the bevacizumab-sensitive
(Tu138) and -resistant (SCC61) HNSCC cell lines by performing antibody array using con-
ditioned media. We found higher expression of both pro- and antiangiogenic factors in
the resistant cells compared to the sensitive cells (Figure 2.2A). The dierentially expressed
proangiogenic factors were IL-8 (264-fold), IL-1 (36-fold), VEGF (20-fold), FGF-a (12-fold)
and TNF- (6-fold) as validated by ELISA (Figure 2.2B-F). Among these cytokines, IL-8
was the most dierentially expressed protein with 264-fold higher expression in the resistant
cells. We then compared IL-8 expression across our panel of HNSCC cell lines and observed
an inverse correlation between IL-8 levels and the in vivo sensitivity of these cell lines to
bevacizumab (Figure 2.2G). These results suggest that IL-8 levels might predict response to
bevacizumab and that IL-8 might be involved in bevacizumab-associated intrinsic resistance
in our HNSCC xenograft models.
Since we observed a signicantly higher expression of VEGF (20-fold) in the resistant
cells compared to the sensitive cells, we also measured plasma human VEGF levels from the
respective xenograft models to further conrm that the intrinsic resistance was not due to
incomplete inhibition of VEGF in the bevacizumab-treated tumors (Figure 2.3).
We also examined the dierentially expressed proangiogenic factors in HNSCC tumors
compared to normal tissues from 3 independent gene expression datasets [84{86] using the
oncomine resource (www.oncomine.org) (Figure 2.4). In these datasets, gene expression is
represented as log2 median-centered intensity and results are expressed as mean fold changes
(tumor versus normal). The P-values were determined using student's t-test. Among the
cytokines analyzed, IL-8 was the most signicantly overexpressed gene in HNSCC tumors
compared to normal control tissues.
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(A) (B) (C) (D)
(E) (F) (G)
Figure 2.2: Resistant HNSCC cells secrete higher levels of several angiogenic factors
including IL-8. (A), in vitro angiogenic prole of bevacizumab-sensitive (Tu138) and -resistant
(SCC61) HNSCC cell lines was examined using antibody array. Conditioned medium was collected
after 48 hours and incubated with Panomics angiogenesis antibody array membranes. The growth
factors that were analyzed are indicated in the bottom panel; pos, positive controls, neg, negative
controls. (B)-(F), Quantitative analysis of proangiogenic proteins (IL-8; P=0.0003, IL-1; P =
0:0092, VEGF; P = 0:0021, FGF-a; P = 0:0073, and TNF-; P = 0:0004) was carried out in the
supernatant from sensitive and resistant cells using ELISA. (G), Comparative analysis of secreted
IL-8 levels in the panel of HNSCC cell lines by ELISA.
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Figure S2
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(A) (B)
Figure 2.3: Inhibition of VEGF in bevacizumab-treated sensitive and resistant tumors.
Human VEGF levels were measured in plasma from mice bearing sensitive and resistant tumors
that were treated with saline or bevacizumab (4mg/kg). Bevacizumab treatment resulted in a
signicant reduction in VEGF plasma levels in both sensitive/Tu138 (A) tumors (98% inhibition;
P = 0:0383) and resistant/SCC61 (B) tumors (87% inhibition; P = 0:0270).
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Figure 2.4: Expression of proangiogenic factors in HNSCC tumors compared to normal
tissues from publically available microarray datasets in Oncomine.
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2.3.3 IL-8 mediates rescue of in vitro angiogenesis in bevacizumab-treated en-
dothelial cells
To test our hypothesis that IL-8 contributes to resistance to bevacizumab, we examined the
ability of IL-8 to support endothelial cell proliferation, migration and capillary-tube forma-
tion in the presence of VEGF and bevacizumab.
We did not observe any signicant dierence in the rate of proliferation between bevacizumab-
inhibited HUVECs in the presence and absence of IL-8 stimulation using the MTT assay
(Figure 2.5A).
In a transwell migration assay, bevacizumab caused a 25% reduction in the number of
migrated cells in VEGF-stimulated HUVECs (Figure 2.5B). Interestingly, addition of IL-8
to bevacizumab-treated HUVECs fully restored cell migration. Consistently, VEGF induced
capillary-tube formation in HUVECs and this eect was abrogated by bevacizumab (Fig-
ure 2.5C-D). However, the addition of IL-8 to bevacizumab-treated HUVECs resulted in a
signicant recovery of capillary-tube formation. These results indicate that IL-8 could com-
pensate for VEGF in setting of bevacizumab-mediated inhibition of in vitro angiogenesis. In
conjunction with the rescue eect of IL-8, we were interested to see if IL-8 modulated in vitro
angiogenesis phenotype-associated proteins that are common to VEGF and IL-8 downstream
signaling cascades, such as Akt (Figure 2.6A-B). Bevacizumab caused a signicant reduction
in pAkt levels in VEGF-stimulated HUVECs. However, IL-8 restored the phosphorylation
of Akt thereby overcoming the eect VEGF inhibition. These data suggest that the rescue
eects of IL-8 to promote in vitro angiogenesis and restore pAkt in endothelial cells could
in part be contributing to resistance to anti-VEGF therapy.
2.3.4 Downregulation of IL-8 in resistant xenografts leads to bevacizumab-
sensitivity
In vitro studies on the compensatory function of IL-8 in endothelial cells provided a ratio-
nale to simultaneously target VEGF and IL-8 in bevacizumab-resistant tumors. To perform
this loss-of-function analysis, we downregulated IL-8 expression in the resistant cell lines
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Figure 2.5: IL-8 mediates rescue of in vitro angiogenesis in bevacizumab-treated en-
dothelial cells. (A), HUVECs were treated with medium (4% FBS containing EBM-2) alone or
medium containing VEGF, IL-8, or bevacizumab. MTT assay was performed at the start of the
experiment and after 24 hrs. (B), HUVECs were plated onto transwell lters in dierent treatment
media. After 24 hrs, transwell lters were stained and number of migrated cells was assessed.
Bevacizumab signicantly reduced the number of migrated cells compared to VEGF alone (?;
P = 0:0010) while addition of IL-8 restored migration (#; P=0.0077). (C), HUVECs were plated
in 24-well plates precoated with type I collagen gels in dierent treatment media. After 24 hrs of
incubation, plates were examined for capillary-tube formation by microscopy. (D), Quantitative
analysis of capillary-tube formation was performed by counting the number of tubes. Bevacizumab
markedly reduced the number of tubes compared to VEGF alone (?; P = 0:0011) while addition
of IL-8 signicantly recovered tubule formation (#; P = 0:0142).
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Figure 2.6: IL-8 mediates rescue of in vitro angiogenesis phenotype-associated proteins
in bevacizumab-treated endothelial cells. (A), IL-8 mediated restoration of pAKT protein
levels in HUVECs by western blotting. (B), Bars represent average densitometric values of pAKT
normalized to total AKT from three independent experiments.
(FaDu and SCC61) using an shRNA approach. These resistant cell lines were transduced
with control shRNA or IL-8 shRNA expressing lentivirus and marked reduction in IL-8 lev-
els were conrmed using ELISA (Figure 2.7A-B). The transduced cells were then used to
produce xenografts in nude mice and tumor growth was assessed in the absence or presence
of bevacizumab. For the HNSCC cell line FaDu, neither treatment with bevacizumab nor
downregulation of IL-8 resulted in statistically signicant decrease in tumor growth, conrm-
ing the resistant nature of these xenografts (Figure 2.7C). However, downregulation of IL-8
conferred sensitivity to bevacizumab as evidenced by almost complete inhibition of tumor
growth. For the HNSCC cell line SCC61, treatment with bevacizumab and the downregu-
lation of IL-8 both resulted in modest but statistically signicant decrease in tumor growth
(Figure 2.7D). However, similar to FaDu, the greatest degree of inhibition was seen with
bevacizumab treatment in setting of IL-8 downregulation.
Using immunohistochemical and immunouorescence analysis, we further analyzed MVD
and endothelial cell apoptosis in these xenografts to conrm whether the combination treat-
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ment reversed the angiogenic escape in resistant tumors. Both, treatment with bevacizumab
and downregulation of IL-8, reduced MVD and increased endothelial cell apoptosis in the
FaDu xenografts (Figure 2.8A-C) as well as the SCC61 xenografts (Figure 2.8A-C). However,
the largest dierence was seen with combined inhibition. Collectively, the above data show
that IL-8 contributed to bevacizumab resistance in our HNSCC tumor models by circum-
venting inhibition of VEGF-mediated angiogenesis.
2.3.5 Upregulation of IL-8 in sensitive xenografts leads to bevacizumab-resistance
To further substantiate our ndings on the role of IL-8 in mediating bevacizumab resistance
and to provide counter evidence, we employed a gain-of-function approach to upregulate IL-8
expression in the sensitive tumors and examine emergence of resistance. HNSCC cell line
Tu138 was transfected with control or IL-8 expressing vector followed by conrmation of the
overexpression using ELISA (Figure 2.10A). Nude mice were subcutaneously implanted with
control or IL-8 overexpressing cell lines. Mice were grouped and treated with saline or beva-
cizumab. As expected, the control xenografts showed signicant sensitivity to bevacizumab.
However, the IL-8 overexpressing xenografts became refractory to bevacizumab and these
xenografts grew at rates similar to saline-treated control xenografts regardless of whether
they were treated with saline or bevacizumab (Figure 2.10A-B). CD31 staining in these
xenografts revealed signicantly higher MVD in bevacizumab-treated IL-8 overexpressing
xenografts compared to the control xenografts (Figure 2.11A-B).
2.3.6 Serum IL-8 levels in HNSCC patients treated with cetuximab and beva-
cizumab suggest correlation with clinical response
As our data identied IL-8 as a mediator of bevacizumab resistance in preclinical HNSCC
xenograft models, we next assessed IL-8 levels in sera from HNSCC patients who received
bevacizumab as a part of their treatment regimen and correlated these levels with clinical
outcome (Figure 2.12). Serum samples were obtained from patients enrolled in a phase II
clinical trial of bevacizumab plus cetuximab [80]. In this trial, 43 patients with recurrent
or metastatic HNSCC received bevacizumab (15mg/kg IV every 21 days) and cetuximab
(200mg/m2 IV once per week after a loading dose of 400mg/m2) until progress of their
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Figure 2.7: Combined knockdown of VEGF and IL-8 signicantly inhibits tumor
growth in resistant xenografts. (A-B), Knockdown of IL-8 gene in FaDu (A) and SCC61 (B)
cells lines. HNSCC cells were infected by control shRNA or IL-8 shRNA lentivirus and cell culture
supernatant was subsequently collected for ELISA. (C), Nude mice (n = 10) were subcutaneously
implanted with FaDu-control or shIL8 cell lines. After tumor formation, mice were grouped and
given saline or bevacizumab. Mean tumor volumes were compared using student's t-test. Asterisks
indicate signicant dierence (p < 0:05) when comparing bevacizumab alone versus bevacizumab
treated shIL8 xenografts (?; P = 0:0165). (D), Similarly, nude mice (n = 20) were subcutaneously
implanted with SCC61-control or shIL8 cell lines and mean tumor volumes in treated groups were
compared (?; P=0.0025).
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Figure 2.8: Combined knockdown of VEGF and IL-8 disrupts vasculature in resistant
FaDu xenografts. (A-C), Microvessel density and endothelial cell apoptosis was assessed in the
FaDu xenografts treated with bevacizumab and/or shIL8 by staining for CD31 (red) and or co-
staining for TUNEL (green). Combination treatment reduced microvessel density (P = 0:0439)
and increased endothelial cell apoptosis (P = 0:0310) in FaDu tumors compared to bevacizumab
alone.
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Figure 2.9: Combined knockdown of VEGF and IL-8 disrupts vasculature in resistant
SCC61 xenografts. (A-C), Microvessel density and endothelial cell apoptosis was assessed in
the SCC61 xenografts treated with bevacizumab and/or shIL8 by staining for CD31 (red) and or
co-staining for TUNEL (green). Combination treatment reduced microvessel density (P = 0:0001)
and increased endothelial cell apoptosis (P = 0:0012) in SCC61 tumors compared to bevacizumab
alone.
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Figure 2.10: Upregulation of IL-8 in sensitive xenografts leads to bevacizumab-
resistance. (A), Tu138 cells were transfected with control or IL-8 expressing vector followed
by conrmation of the overexpression using ELISA (?; P < 0:0001). (B), Nude mice (n=10) were
subcutaneously implanted with control or IL-8 overexpressing cell lines. After tumor formation,
mice were grouped and given saline or bevacizumab. IL-8 overexpressing xenografts became re-
fractory to bevacizumab resulting in a dramatic increase in tumor growth compared to the control
xenografts treated with bevacizumab (?; P = 0:0011).
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Figure 2.11: Upregulation of IL-8 leads to increased vasculature in sensitive xenografts.
(A), CD31 staining in IL-8 overexpressing and control Tu138 xenografts using immunohistochem-
istry. (B), MVD analysis indicated increased number of vessels in bevacizumab-treated IL-8 over-
expressing xenografts compared to bevacizumab-treated control xenografts (?; P < 0:0001).
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disease. Baseline serum samples were available from 32 patients. Serum level of IL-8 was
noted to be 40% higher at baseline in patients with no response (progressive disease or stable
disease) compared to those with partial response (PD/SD= 54:4 pg/ml, PR= 33:0 pg/ml).
However, this dierence in serum IL-8 levels was not statistically signicant (P = 0:2315).
Although we observe an encouraging trend in serum IL-8 levels and clinical response to
bevacizumab, this analysis is limited by small number of patients in partial response group
(n = 4). Hence, validation in a larger cohort of patients is warranted.
2.3.7 Constitutively activated PI3K signaling transactivates IL8 production in
resistant cells
It has been reported that bevacizumab-resistant SCC61 cells contain a PI3K activating mu-
tation (E542K) in Exon 9 [87]. We next examined if activated PI3K aected IL-8 production
levels in the resistant cells (Figure 2.13). SCC61 cells were treated with DMSO control or
NVP-BEZ235 (dual PI3K/mTOR inhibitor) for 24 hrs followed by western blot analysis to
determine IL-8 levels. Treatment with NVP-BEZ235 resulted in a dose-dependent decrease
in IL-8 levels. These results suggest that constitutive activation of PI3K signaling in the
resistant cells regulates increased production of IL-8 in the resistant cells.
2.3.8 IL-1 positively regulates IL-8 & VEGF in resistant cells
In addition to PI3K signaling contributing to increased IL-8 levels, we also examined other
mechanisms of IL-8 regulation in the resistant cells. Studies have shown that IL-1 promotes
nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in
head and neck squamous cell carcinomas [88]. To conrm these ndings in our HNSCC
models, we downregulated IL-1 in SCC61 cells using shRNA approach (Figure 2.14A). We
then measured IL-8 (Figure 2.14B) and VEGF (Figure 2.14C) levels in the IL-1 knock-
down cells using ELISA. We observed a signicant decrease in IL-8 and VEGF expression
in IL-1 knockdown cells compared to the vector control. Also, previous experiments have
shown that the resistant cells express increased levels of IL-1 along with IL-8 and several
other proangiogenic proteins (Figure 2.2C). Collectively, these data suggest that increased
expression of IL-1 in the resistant cells contributes to increased IL-8 production, which me-
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Figure 2.12: IL-8 levels in sera of HNSCC patients treated with cetuximab and be-
vacizumab. IL-8 expression levels were examined in sera from 32 patients with recurrent or
metastastic HNSCC who were treated with bevacizumab and cetuximab. Within this cohort, there
were 28 non-responders (those with progressive disease or stable disease) and 4 partial responders.
Serum IL-8 was higher at baseline in patients with no response compared to those with partial
response, although not statistically signicant (P = 0:2315). Data are expressed as means  SEM.
P-values are derived from a two-tailed probability generated from a Mann-Whitney test.
Figure 2.13: Constitutively activated PI3K signaling transactivates IL8 production in
resistant cells. SCC61 cells were treated with DMSO control or NVP-BEZ235 (dual PI3K/mTOR
inhibitor) for 24 hrs followed by western blot analysis to determine IL-8 levels. Treatment with
NVP-BEZ235 resulted in a dose-dependent decrease in IL-8 levels.
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Figure 2.14: IL-1 positively regulates IL-8 & VEGF in resistant cells. (A), Downregu-
lation IL-1 in SCC61 cells using shRNA approach. (B-C), IL-8 (B) and VEGF (C) expression in
IL-1 downregulated cells using ELISA. Mean values of proteins levels were compared using stu-
dent's t-test. P-value < 0:05 was considered signicant (?). IL-1, P = 0:0051; IL-8, P = 0:0091;
VEGF, P = 0:0091.
diates bevacizumab resistance. Hence, increased IL-1 signaling could be another potential
mechanism of resistance to anti-VEGF therapy in HNSCC.
2.4 CONCLUSIONS AND DISCUSSION
In this study, we investigated the in vivo ecacy of bevacizumab in several HNSCC xenograft
models and found high expression of IL-8 in the bevacizumab-resistant tumors. IL-8, also
known as CXCL-8 is a potent proinammatory cytokine that belongs to the CXC chemokine
family of proteins. In addition to its inammatory role, IL-8 is known to play an important
role in angiogenesis, tumor growth and metastasis [89,90]. Here, we showed that modulation
of IL-8 expression in HNSCC xenografts directly controlled the sensitivity of these xenografts
to the antitumor and antiangiogenic eects of bevacizumab. We also identied PI3K and
IL1- signaling as the molecular basis for overexpression of IL-8 in the resistant tumors.
It has been previously reported that SCC61 cells (bevacizumab-resistant) contain a PI3K
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activating mutation (E542K) in Exon 9 [87]. Our studies showed that treatment with NVP-
BEZ235 (dual PI3K/mTOR inhibitor) resulted in a dose-dependent decrease in IL-8 levels.
These data suggest that constitutive activation of PI3K signaling in the resistant cells could
serve as an escape mechanism to anti-VEGF therapy by regulating increased production of
IL-8.
In addition to PI3K signaling, we also demonstrated IL-1 as a mechanism IL-8 regu-
lation in the resistant cells. Studies have shown that IL-1 promotes nuclear factor-kappa
B and Activator Protein-1 induced IL-8 expression, cell survival, and proliferation in head
and neck squamous cell carcinomas [88]. We validated these ndings in our HNSCC models,
by downregulating IL-1 in SCC61 cells using shRNA approach and observed a signicant
decrease in IL-8 and VEGF expression. Also, in our antibody array analysis, we have shown
that the resistant cells express increased levels of IL-1 along with IL-8 and several other
proangiogenic proteins. These ndings suggest that increased expression of IL-1 in the resis-
tant cells contributes to increased IL-8 production, which mediates bevacizumab resistance.
Hence, IL-1 signaling could be another potential mechanism of resistance to anti-VEGF
therapy in HNSCC.
The exact mechanism by which IL-8 obviates the need for VEGF during tumor angio-
genesis is unclear. However, one possible explanation is that IL-8 is able to act directly
on endothelial cells and activate endothelial pathways that ultimately result in resistance to
anti-VEGF therapy. It is well established that endothelial cells express CXCR1 and CXCR2,
the cognate receptors for IL-8, and that IL-8 is a proangiogenic molecule [91,92]. Conversely,
administration of inhibitors of the IL-8 pathway to animals bearing tumor xenografts results
in decreased MVD [93,94]. In our in vitro studies, we showed that IL-8 functionally replaced
VEGF in mediating migration and capillary-tube formation in endothelial cells in presence
of bevacizumab. Furthermore, addition of IL-8 to bevacizumab-treated endothelial cells re-
stored the activation levels of signaling molecules that are common to both VEGF and IL-8
pathways such as Akt. Our in vivo studies further validated these ndings where combined
targeting of VEGF and IL-8 lead to signicantly reduced MVD and increased endothelial
39
cell apoptosis compared to inhibition of either protein alone.
The exact eects of IL-8 on the tumor endothelium that lead to resistance to anti-VEGF
therapy have yet to be dened clearly. However, a potential mechanism can be proposed
based on a study by Petreaca et. al. [95]. This study showed that IL-8 is able to induce the
transactivation of VEGFR2 in endothelial cells. Furthermore, this interaction was found to
be due to direct interaction between VEGFR2 and CXCR1/ CXCR2, and was independent
of extracellular VEGF. In our studies with murine endothelial cells we have found a similar
induction of pVEGFR2 levels with IL-8.
It is also possible that IL-8 may act on other elements of the tumor microenvironment,
which then act on the endothelial cells to produce resistance to anti-VEGF therapy. Possible
candidates from the tumor microenvironment that may act in this intermediary role include
stromal cells such as broblasts and tumor inltrating myeloid derived cells. Although IL-8
was rst identied by chemotatic property on neutrophils, it also has chemotactic eects on
broblasts [96]. Cascone et. al. [76] has shown in a recent study that stromal upregulation
of EGFR and FGFR may be involved in resistance to bevacizumab therapy in preclinical
lung cancer models. Similarly, Shojaei et. al. [97] has shown that murine xenografts resis-
tant to anti-VEGF agents express cytokines such as granulocyte colony stimulating factor
(G-CSF), which induces the inltration of the tumor xenografts by CD11b+Gr1+ myeloid
cells. These myeloid cells produce Bv8, a secreted protein with angiogenic properties, which
then promote angiogenesis in the absence of VEGF [98,99]. Although we have not assessed
our model for dierences in tumor-inltrating myeloid cells or lymphocytes, the proinam-
matory properties of IL-8 suggest that its inuence on the tumor microenvironment may be
a major factor leading to resistance.
We also examined the IL-8 expression levels in sera from HNSCC patients before treat-
ment with VEGF-targeting monoclonal antibodies. High IL-8 levels were observed exclu-
sively in a subset of patients in the non-responder group but not in the partial responders.
Although there were no signicant dierences in median values of IL-8 between the two pa-
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tient groups, the observed trends are encouraging and consistent with previous reports that
indicate an inverse correlation of IL-8 levels with progression free survival and increased pro-
gression risk [100, 101]. The recent preclinical study by Huang et. al. [67] also showed that
IL-8 expression was elevated in human RCC tumors refractory to tyrosine kinase inhibitor
sunitinib. In the light of these preclinical and clinical ndings, we foresee IL-8 to be an
important player in governing sensitivity to antiangiogenic therapy in HNSCC. Hence, fu-
ture clinical trials with angioangiogenic agents that assess IL-8 levels in patients will further
validate the use of IL-8 as a relevant biomarker of treatment response or resistance.
Lastly, there are limitations to this study that should be acknowledged. The study was
performed using human xenografts in a murine model and bevacizumab. It is known that
bevacizumab binds poorly to murine VEGF and therefore, the role of murine VEGF in our
model of resistance is unclear [102]. Secondly, it should be noted that the patients on our
clinical trial did not receive single-agent therapy with bevacizumab but rather received both
bevacizumab and cetuximab. IL-8 has been implicated as a predictive biomarker in cetux-
imab therapy [103] and irinotecan plus bevacizumab-based therapy [104] in colorectal cancer.
As such, serum IL-8 data from our study may reect treatment eects of both cetuximab and
bevacizumab. Furthermore, the dierence in the serum levels of IL-8 between patients with
progressive disease/ stable disease and those with partial response did not reach statistical
signicance.
In summary, this study reveals IL-8 as one of the contributors of bevacizumab resistance
in HNSCC tumor models. Several IL-8 agents are currently in clinical development primarily
for the treatment of inammatory diseases and these agents have shown antitumor and
antiangiogenic activity in preclinical models [105,106]. Our data suggests that the concurrent
use of anti-VEGF drugs such as bevacizumab and IL-8 targeting agents may help overcome
resistance and improve therapeutic ecacy of antiangiogenic therapy in HNSCC.
41
3.0 HNSCC XENOGRAFT MODELS OF ACQUIRED RESISTANCE TO
BEVACIZUMAB
3.1 INTRODUCTION
Preclinical and clinical studies from several cancers indicate that the therapeutic benets of
bevacizumab are transitory and are followed by disease progression within a few months of
treatment [107{111]. Similar responses are seen in HNSCC [55, 56, 81], where bevacizumab
is being evaluated in phase III clinical trials (NCT00588770). Available evidence suggests
that tumors can adapt to the eects of these angiogenic inhibitors by acquiring alternative
ways to sustain growth and survival. Studies using relevant preclinical models that identify
these alternative-signaling pathways, which mediate angiogenic rescue in the bevacizumab-
resistant tumors will help develop reliable resistance biomarkers.
Here, we investigated the mechanisms of acquired resistance to bevacizumab in preclin-
ical HNSCC models. HNSCC cell line, Tu138 that exhibited high in vivo sensitivity to
bevacizumab (from the dierential sensitivity screen in Section 2.3.1) was used to generate
and validate preclinical models of acquired resistance. In order to establish the xenograft
model, we used an incremental drug dosing regime, which eliminated the sensitive tumor
cells and sequentially selected for the resistant clones. After prolonged therapy, we observed
a signicant dierence in the tumor growth between the chronically treated Tu138 xenografts
(less sensitive) and the isogenic parental (more sensitive) xenografts. To identify molecular
changes initiated by tumor cells, we performed human-specic microarray analysis on the
isogenic pair of bevacizumab-sensitive and -resistant tumors. We further examined the dif-
ferentially expressed proteins in vivo for their involvement in conferring acquired resistance,
using a combinatorial approach.
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3.2 MATERIALS AND METHODS
3.2.1 Cell lines and reagents
Tu138 cells and the bevacizumab-resistant isogenic clones TuR3 were maintained in DMEM/F12
medium supplemented with 10% FBS. Both cell lines were validated by genotyping using
short tandem repeat analysis [83]. Bevacizumab was purchased from the University of Pitts-
burgh Pharmacy. PD173074 was purchased from Selleck Chemicals (Houston, TX).
3.2.2 Animal studies
3.2.2.1 Model of acquired resistance To generate the preclinical model, we inocu-
lated Tu138 cells (3  106 cells/ mouse) in athymic nude mice (n = 10). After formation
of subcutaneous tumors ( 2 weeks), these mice were randomized to receive vehicle or be-
vacizumab and treated biweekly by intraperitoneal injection. Tumors were also measured
biweekly and mean tumor volumes were computed as previously described in Section 2.2.2.
Bevacizumab was administered at a moderate dose of 4mg/kg followed by incrementing the
dose by 4mg/kg with every subsequent increase in tumor volume. Drug concentration was
increased upto the maximum-tolerated dose in patients (20mg/kg). Mice were sacriced if
the tumors exceeded 20mm in diameter. Resistant tumors were excised and small tumor
fragments ( 1mm in diameter) were reimplanted into new mice (n = 2) to propagate the
model. Mice were treated with saline or bevacizumab (increasing concentrations, 8mg/kg-
20mg/kg) for a period of two months.
3.2.2.2 Validation experiments Resistant tumor-derived cells were expanded in vitro
for reinoculation and validation in a second in vivo study with a short-term treatment regime
(4 weeks). Resistant cells from tumors TuR1, TuR2 and TuR3 were inoculated in mice (n=6).
Two weeks after tumor cell inoculation, the mice were randomized to receive vehicle or be-
vacizumab (4mg/kg).
Small fragments from the resistant tumor (TuR3) were implanted to generate xenografts
(n = 4) for validation in a separate in vivo study. Parental Tu138 cells were also inoculated
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in mice (n = 4) as a positive control for sensitivity to bevacizumab. After two weeks, the
mice were treated with vehicle or bevacizumab (4mg/kg).
In another in vivo study, small fragments from a bevacizumab-nave parental Tu138
tumor were implanted in mice (n = 10) to create xenografts. Mice were treated with saline
or bevacizumab (4mg/kg).
3.2.2.3 Combination experiments For the combination treatment study, small frag-
ments from the resistant tumor were implanted in mice (n = 12). Mice were randomized
into four treatment groups receiving saline, bevacizumab, PD173074 or a combination of be-
vacizumab and PD173074. Bevacizumab and PD173074 were administered intraperitoneally
at 8mg/kg (biweekly) and 25mg/kg (daily) respectively. Tumors were measured daily and
tumor growth was assessed for two weeks.
3.2.3 Immunohistochemistry and immunouorescence
Frozen tumor sections (8   10 mm) from each group were mounted on positively charged
Superfrost slides (Fischer Scientic, Houston, TX). The slides were washed in Tris Buer
Saline/ Tween 20 and incubated in endogenous peroxidase and protein blocking solution Ro-
dent block (BioCare, Concord, CA). The samples were then incubated with rat anti-mouse
CD31 antibody (BD Biosciences Pharmingen, San Jose, CA). After washing, the slides were
incubated in rat Probe followed by Rat polymer (Biocare Rat on Mouse Kit). The slides
were then incubated in chromogen DAB Quanto (Thermo Scientic/Lab Vision, Kalamazoo,
MI). Slides were stained in Mayers Hematoxilin and coversliped with Permount.
Frozen tumor sections were xed and blocked as above, excluding the endogenous per-
oxidase step. The slides were incubated with rat anti-mouse CD31 monoclonal antibody,
washed with PBS, blocked with protein block and incubated with Texas Red-X goat anti-
rat IgG antibody (Invitrogen, Grand Island, NY). To stain for terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL), a commercially available Apopto-
sis Detection kit (Promega, Madison, WI) was used. Slides were washed with PBS and
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mounted using Vectashield Mounting Medium with DAPI (Vector laboratories, Burlingame,
CA). Immunouorescence microscopy was carried out using an Olympus IX81-DSU Spinning
Disk Confocal Microscope. Images were captured using a Hamamatsu ORCA II ER camera
(Hamamatsu Corp.) and 3i Slidebook 5.0 software.
For quantication of CD31 expression, vessels completely stained with anti-CD31 anti-
bodies were counted in random 0.04-mm2 elds at using a 20 objective. Quantication of
CD31/TUNEL staining was done as the average percentage of apoptotic endothelial cells in
10 random 0.01-mm2 elds using a 40 objective.
3.2.4 Microarray
Total RNA was extracted from frozen tumors using TRIzol reagent (Invitrogen/Life Tech-
nologies Grand Island, NY) and puried using the RNeasy Kit (Qiagen, Germantown, MD).
RNA amplication and biotin labeling was done using Illumina Total Prep RNA Amplica-
tion Kit (Ambion Inc.). Biotinylated cRNA was hybridized to human HT-12 v4 BeadChips
(Illumina Inc., San Diego, CA) and scanned using an Illumina BeadChip Array Reader.
Eciency analysis was used to determine the optimal methods for data normalization,
transformation, and feature selection that produced the most internally consistent gene set.
Raw data were normalized using a log2 and z-transformation and dierentially expressed
genes were identied using J5 test [112]. Gene expression changes were considered to be
statistically signicant for genes bearing a J5 score higher than the threshold value 8:0. A
pathway level impact analysis [113], was performed to provide both statistical and biolog-
ical signicance in suggesting the potential pathways aected by the observed changes in
gene expression. The results are summarized as impact scores and p-values. Dierentially
expressed genes between bevacizumab-sensitive and -resistant tumors were also subjected to
the functional interaction network analysis using Ingenuity Pathways Analysis (IPA) soft-
ware.
45
3.2.5 Real-time RT-PCR
Real-time RT-PCR was performed using taqMan one-step RT-PCR master mix kit and
taqman gene expression assay kits (Applied Biosystems/ Life Technologies Grand Island,
NY) on a 7900HT Real-Time PCR system (Applied Biosystems/ Life Technologies Grand
Island, NY). Samples were prepared in triplicates in a 20l reaction volume containing
200ng input RNA. RT-negative controls were run on each plate to ensure no amplication
in the absence of input RNA. Standard cycling conditions were programmed as: 95 C for
12 minutes, 40 cycles of: 95 C for 15 seconds, 60 C for 1 minute. -Actin was used as
endogenous control. Following gene-specic Taqman gene expression assay kits were used;
FGF2: Hs00266645 m1, FGFR3: Hs00179829 m1, and PLCg2: Hs00182192 m1.
3.2.6 Western
Parental Tu138 cells and bevacizumab-resistant clones TuR3 were plated in 10cm dishes. The
following day complete medium was replaced with serum free medium. After 24 hrs, cells
were treated with MEK inhibitor U0126 for 6 hrs and whole cell lysates were prepared and
resolved on 10% SDS-page gels. Following transfer onto nitrocellulose membranes, antibody
staining was done using: pERK (Thr202/Tyr204), ERK, FGF2 and -Actin (Cell Signaling
Technology Inc., Danvers, MA). Reactive bands were detected by chemiluminiscence using
ECL plus western blotting detection kit (Amersham Biosciences, Piscataway, NJ). Similarly,
immunoblots were performed using untreated cells and siRNA transfected cells using the
following antibodies; FGF1, FGFR1, FGFR3, pPLCg1 (Tyr783), PLCg1, pPLCg2 (Tyr759),
PLCg2, pSrc (Tyr416), Src, pAKT (S473), AKT, CCL5 (Cell Signaling Technology Inc.,
Danvers, MA) FGFR2, FGFR4, FZD4, and CX3CL1 (Abcam, Cambridge, MA).
3.2.7 ELISA
Parental Tu138 cells and bevacizumab-resistant clones TuR3 were plated at a density of 5
106 cells/ 10cm dish. Cell culture supernatant was collected after 24 hours and centrifuged at
1200rpm for 5 min. CCL5 was measured in cell culture supernatants from siRNA transfected
cells using ELISA kit (R&D Systems, Inc., Minneapolis, MN) as per the manufacturer's
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instructions.
3.2.8 siRNA Transfection
Parental Tu138 cells and bevacizumab-resistant clones TuR3 were transfected with siRNA
targeting FZD4, PLCg2, CX3CL1, CCL5 and negative control siRNA (non-targeting) using
Opti-MEM media, lipofectamine-2000 (Invitrogen/ Life Technologies Grand Island, NY).
After 4 hrs, the media was replaced with complete medium and cells were incubated at 37 C
for 1hr. Following incubation, transfected cells were replated in 6-cm plates for western blot
analysis after 48hrs of transfection. Following gene-specic siRNA were used; FZD4: s15840,
PLCg2: s10634, CX3CL1: s12629, and CCL5: s12575.
3.2.9 Statistical Analysis
Data are expressed as mean  S.E.M. Student's t test was used for all statistical analyses.
Signicance tests were performed with a two-sided signicance level of 0:05.
3.3 RESULTS
3.3.1 Generation of HNSCC xenograft model of acquired resistance
In order to establish xenograft model of acquired resistance to bevacizumab, we inoculated
mice with HNSCC cell line Tu138, which has been previously shown to be highly sensitive to
bevacizumab in vivo (Section 2.3.1). After generation of subcutaneous tumors, these mice
were randomized to receive vehicle or bevacizumab at an initial dose of 4mg/kg followed by
incrementing the dose by 4mg/kg with every subsequent increase in tumor volume. Drug
concentration was increased upto the maximum-tolerated dose in patients (20mg/kg). Such
an escalating dosing regime eliminated the sensitive tumor cells and sequentially selected
for the resistant clones. Three out of ve xenograft tumors showed resistance quite early
in the treatment cycle with growth rates comparable to the saline control (Figure 3.1A).
Mean tumor volumes for the resistant xenografts TuR1, TuR2 and TuR3 were 2351.2mm3,
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1329.4mm3 and 1194.0mm3 respectively.
The resistant xenografts were then excised and small tumor fragments ( 1mm in diam-
eter) were reimplanted into new mice (n = 2) to propagate the model (Figure 3.1B-D).
In order to propagate the resistance model, the reimplanted tumors were subjected to a
second phase of treatment where the resistant tumor-bearing mice were treated with saline or
bevacizumab (increasing concentrations, 8mg/kg-20mg/kg) for a period of two months. We
observed a slow emergence of resistance in bevacizumab-treated tumor TuR1 with mean tu-
mor volumes equivalent to the respective saline control (Figure 3.1B). Bevacizumab-treated
tumor TuR2 remained fairly sensitive throughout the treatment suggesting that it failed to
retain the initial resistance under the incremental drug selection pressure (Figure 3.1C). In-
terestingly, we observed a steep increase in tumor growth in the bevacizumab-treated tumor
TuR3 beyond day 36 (Figure 3.1D). Mean tumor volumes at the end of the treatment were
2571.1mm3 as compared to 1326.7mm3 in tumor TuR1. Hence, we selected tumor TuR3 to
validate the acquisition of resistance.
In the validation study, we inoculated parental Tu138 cells as a positive control for sensi-
tivity to bevacizumab and implanted small tumor fragments from the resistant tumor (TuR3)
instead of using in vitro expanded cells to generate xenografts (Figure 3.2A). The parental
tumors were sensitive to bevacizumab, as expected, resulting in 88% growth inhibition. In
contrast, in the resistant tumors there was no signicant reduction in tumor growth.
We then conrmed that the resistant phenotype was not an artifact of reimplanting the
resistant tumors as fragments in contrast to the parental tumors, which were generated by
inoculating cells (Figure 3.2B). Small tumor fragments from a parental tumor that was not
subjected to bevacizumab were implanted in mice to create xenografts. The mice were treated
with saline or bevacizumab and we observed that the parental tumors retained sensitivity
to bevacizumab.
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(A) (B)
(C) (D)
Figure 3.1: Generation of HNSCC xenograft model of acquired resistance to beva-
cizumab. (A), Growth curve of Tu138 xenografts (n = 5 per group) treated with saline or
bevacizumab at an initial dose of 4mg/kg followed by incrementing the dose by 4mg/kg with ev-
ery subsequent increase in tumor volume. 3/5 xenograft tumors (TuR1, TuR2 and TuR3) showed
resistance with growth rates comparable to the saline control. (B-D), Resistant xenografts were
excised and small tumor fragments (1mm in diameter) were reimplanted into new mice (n = 2)
to propagate the model. The reimplanted tumors were subjected to a second phase of treatment
with saline or bevacizumab (increasing concentrations, 8mg/kg-20mg/kg). Emergence of resistance
was observed in bevacizumab-treated tumor TuR1 and TuR3 while TuR2 remained fairly sensitive.
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(A) (B)
Figure 3.2: Validation of bevacizumab resistance in HNSCC xenograft model. (A),
Acquired resistance in reimplanted TuR3 resistant tumors was conrmed by treating xenografts
with saline or bevacizumab (n = 4 per group). Parental Tu138 tumors were sensitive to beva-
cizumab resulting in 88% growth inhibition. In contrast, the resistant tumors showed no signicant
reduction in tumor growth. (B), Parental tumors generated by implanting small fragments from
a bevacizumab-nave parental tumor, which were treated with saline or bevacizumab (n = 5 per
group), retained sensitivity to bevacizumab.
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3.3.2 Bevacizumab-resistant tumors exhibit sustained angiogenesis and reduced
apoptosis
To characterize the preclinical model of acquired resistance, we assessed MVD and apop-
tosis in the bevacizumab-sensitive and -resistant xenografts (from the validation study).
Frozen tumor sections were stained with CD31 using immunohistochemistry (Figure 3.3A,
3.3B). Resistant tumors treated with bevacizumab (bevacizumab-resistant) showed signi-
cantly higher MVD compared to parental tumors treated with bevacizumab (bevacizumab-
sensitive). Further, dual immunouorescence staining for TUNEL+/ CD31+ cells was done
to analyze the percentage apoptotic endothelial cells (Figure 3.3A, 3.3C). Bevacizumab-
sensitive tumors showed a signicant increase in endothelial cell-specic apoptosis (6:2%)
compared to bevacizumab-resistant tumors with only 1:8% apoptotic cells. These results
suggest that the bevacizumab-resistant phenotype is associated with revascularization and
reduced cell death.
3.3.3 Bevacizumab-resistant tumors upregulate angiogenesis genes in response
to chronic anti-VEGF therapy
To identify molecular changes initiated by the tumor cells to mediate bevacizumab resistance,
we performed whole genome microarray analysis. Bevacizumab-sensitive and -resistant iso-
genic tumor models were compared for dierences in gene expression using HumanHT-12
v4 BeadChips (Illumina Inc.). Eciency analysis was used to determine the best statistical
method and the dierentially expressed genes were identied using J5 test. We found 150
genes upregulated and 31 genes downregulated in the resistant tumors (Figure 3.4A, Table
A1).
Using Ingenuity Pathway Analysis (IPA) tool, we identied disease, disorder, molecular
and cellular functions enriched among genes dierentially expressed in bevacizumab-resistant
tumors (Tables 3.1 & 3.2). Table 3.3 and 3.4 list top 10 upregulated and downregulated
genes in resistant tumors. Among the angiogenesis-related genes, we found upregulation of
FGF2, FGFR3, PLCg2, FZD4, CX3CL1, and CCL5 in the resistant tumors (Table 3.5).
We also analyzed functional interaction network involving dierential expressed genes and
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(A)
(B) (C)
Figure 3.3: Resistant tumors exhibit sustained angiogenesis and reduced endothelial
cell apoptosis. (A), CD31 staining (brown) in parental and resistant tumor sections using immuno-
histochemistry (upper panel). Immunouorescence staining of CD31 (red) and TUNEL (green) was per-
formed to assess endothelial cell-specic apoptosis (lower panel). (B), Bar graph represents quantication
of vessels in parental and resistant tumors treated with saline or bevacizumab. (C), Quantitative analysis
of CD31+/TUNEL+ cells represented as percentage of apoptotic endothelial cells. Bevacizumab-resistant
tumors showed signicantly higher microvessel density (P = 0:0428) along with reduced endothelial cell
apoptosis (P = 0:0426) compared to parental tumors treated with bevacizumab.
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(A)
(B)
Figure 3.4: Bevacizumab-resistant tumors upregulate angiogenesis genes in response
to chronic anti-VEGF therapy. (A), Gene expression grid displaying 181 dierentially expressed
genes between bevacizumab-sensitive (n=4) (Right column) and bevacizumab-resistant (n=4) (Left
column) tumors. (B), Network analysis using IPA indicates a signicant modulation in the predicted
function FGF/FGFR signaling in bevacizumab-resistant tumors.
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observed FGF2 as a highly connected nodal gene with upregulated proangiogenic genes
FGFR3, PLCg2, CASP1 and BGN (Figure 3.4B). Interestingly, three of these genes FGF2,
FGFR3 and PLCg2 belong to the FGF signaling pathway, which suggests that this axis
might be involved in bevacizumab-associated acquired resistance in our HNSCC xenograft
model.
3.3.4 Upregulation of FGF signaling in resistant xenografts
To test our hypothesis that FGF signaling contributes to bevacizumab resistance, we rst
validated the upregulation of FGF pathway genes in the resistant tumors by real-time RT-
PCR and western blotting. We conrmed a 6-fold increase in the expression of FGF2 mRNA
in bevacizumab-treated resistant tumors compared to bevacizumab-treated parental tumors
(Figure 3.5A). Similarly, we observed a 4.5-fold increase in FGFR3 mRNA and a 8-fold
increase in PLCg2 mRNA (Figure 3.5B-C). Plasma FGF2 protein levels were signicantly
higher in resistant/bevacizumab tumors compared to parental/bevacizumab tumors as shown
by ELISA (Figure 3.6A). We also conrmed increased protein levels of these genes in tumor
cells expanded from the bevacizumab-treated resistant xenografts compared to the parental
Tu138 cell line (Figure 3.6C). Since, we observed an increased expression of the FGF2 lig-
and, FGFR3 receptor and PLCg2 downstream protein in the resistant cells, we assessed
other members of the FGF pathway for increased signaling (Figure 3.6B). Between the two
FGF ligands, we observed increased expression of FGF2 and not FGF1 in the resistant cells.
Among the four FGFR receptors, FGFR1, 2 and 3 were upregulated and FGFR4 was down-
regulated in the resistant cells. Among the downstream proteins, higher levels of phospho
PLCg1, total PLCg1, phospho PLCg2, total PLCg2, phospho AKT and phospho ERK were
seen in the resistant cells.
3.3.5 Increased ERK activation upregulates FGF2 expression in resistant cells
Studies have shown that activated ERK can positively regulate FGF levels [114]. We next
examined if increased ERK activation in the resistant cells upregulated FGF2 expression. To
test this, we treated parental and resistant cells with the MEK inhibitor U0126 to block ERK
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Name P-Value # Molecules
Dermatological Diseases and Conditions 1.4210 20 - 2.1410 2 56
Genetic Disorder 1.4210 20 - 2.1410 2 72
Cancer 2.3910 13 - 2.1410 2 85
Immunological Disease 2.4410 12 - 1.1810 2 36
Inammatory Disease 2.4410 12 - 2.1410 2 34
Table 3.1: Dierentially expressed genes enriched among specic diseases or disorders.
Name P-Value # Molecules
Cell Death 2.3210 6 - 2.1410 2 45
Cellular Movement 1.3810 5 - 2.1410 2 32
Cellular Growth and Proliferation 1.6110 5 - 2.1410 2 50
Carbohdrate Metabolism 2.4810 4 - 1.0910 2 10
Molecular Transport 2.4810 4 - 1.8210 2 17
Table 3.2: Dierentially expressed genes enriched among specic molecular or cellular
functions.
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Rank Description J5-score Accession #
1 hemoglobin, beta (HBB) 27.473 NM 000518.4
2 insulin-like growth factor binding protein 6 (IGFBP6) 27.04 NM 002178.2
3 H19, imprinted maternally expressed transcript (non-
protein coding) (H19), non-coding RNA.
25.785 NR 002196.1
4 alkaline phosphatase, liver/bone/kidney (ALPL), tran-
script variant 1
22.435 NM 000478.2
5 retinoic acid receptor responder (tazarotene induced) 3
(RARRES3)
21.255 NM 004585.2
6 hect domain and RLD 5 (HERC5) 19.807 NM 016323.1
7 keratin 10 (epidermolytic hyperkeratosis; keratosis pal-
maris et plantaris) (KRT10)
18.764 NM 000421.2
8 frizzled homolog 4 (Drosophila) (FZD4) 18.239 NM 012193.2
9 NADH dehydrogenase (ubiquinone) 1 alpha subcom-
plex, 4-like 2 (NDUFA4L2)
17.73 NM 020142.3
10 absent in melanoma 2 (AIM2) 17.325 NM 004833.1
Table 3.3: Top 10 upregulated genes in bevacizumab-resistant tumors.
Rank Description J5-score Accession #
1 small proline-rich protein 2G (SPRR2G) -24.715 NM 001014291.1
2 defensin, beta 103B (DEFB103B) -22.442 XM 928791.1
3 late cornied envelope 3D (LCE3D) -20.282 NM 032563.1
4 small proline-rich protein 2F (SPRR2F) -16.568 NM 001014450.1
5 small proline-rich protein 2A (SPRR2A) -16.539 NM 005988.2
6 PRED: hypothetical protein LOC647993 (LOC647993) -15.078 XM 937048.1
7 ribonuclease, RNase A family, 7 (RNASE7) -15.01 NM 032572.2
8 small proline-rich protein 2E (SPRR2E) -14.686 NM 001024209.2
9 PRED: hypothetical LOC643161 (LOC643161) -14.229 XM 926530.1
10 PRED: similar to Ribosome biogenesis protein BMS1
homolog (LOC647987)
-13.172 XM 937044.1
Table 3.4: Top 10 downregulated genes in bevacizumab-resistant tumors.
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Rank Description J5-score Accession #
1 insulin-like growth factor binding protein 6 (IGFBP6) 27.04 NM 002178.2
2 frizzled homolog 4 (Drosophila) (FZD4) 18.239 NM 012193.2
3 chemokine (C-X3-C motif) ligand 1 (CX3CL1) 13.329 NM 002996.3
4 chemokine (C-X-C motif) receptor 7 (CXCR7) 13.142 NM 020311.1
5 phospholipase C, gamma 2 (phosphatidylinositol-
specic) (PLCG2)
12.871 NM 002661.1
6 biglycan (BGN) 12.165 NM 001711.3
7 XIAP associated factor 1 (XAF1), transcript variant 2 11.535 NM 199139.1
8 chemokine (C-C motif) ligand 5 (CCL5) 10.718 NM 002985.2
9 regulator of G-protein signalling 2, 24kDa (RGS2) 10.661 NM 002923.1
10 interferon regulatory factor 1 (IRF1) 10.254 NM 002198.1
11 Kruppel-like factor 4 (gut) (KLF4) 10.163 NM 004235.3
12 broblast growth factor 2 (basic) (FGF2) 9.741 NM 002006.3
13 caspase 1, apoptosis-related cysteine peptidase (inter-
leukin 1, beta, convertase) (CASP1), transcript variant
alpha
9.477 NM 033292.2
14 insulin receptor substrate 1 (IRS1) 8.817 NM 005544.1
15 broblast growth factor receptor 3 (achondroplasia,
thanatophoric dwarsm) (FGFR3), transcript variant
2
8.424 NM 000142.2
Table 3.5: Angiogenesis-related genes upregulated in bevacizumab-resistant tumors.
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(A) (B)
(C)
Figure 3.5: Increased expression of FGF2/ FGFR3/ PLCg2 mRNA in resistant
xenografts. (A)-(C), qRT-PCR analysis of FGF2, FGFR3 and PLCg2 mRNA levels reveal
6-fold, 4.5-fold and 8-fold increase in expression in resistant/bevacizumab tumors compared
to parental/bevacizumab tumors respectively (FGF2; P=0.0002, FGFR3; P=0.0439, PLCg2;
P=0.0160).
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(A)
(B)
(C)
Figure 3.6: Upregulation of FGF signaling in resistant xenografts. (A), Plasma
FGF2 protein levels were signicantly higher in resistant/bevacizumab tumors compared to
parental/bevacizumab tumors (P=0.0441) as shown by ELISA. (A), Western blot analysis con-
rmed increased protein levels of FGF2, FGFR3 and PLCg2 in tumor cells expanded from
bevacizumab-treated resistant xenografts compared to the parental Tu138 cell line. (A), Increased
expression of FGF2 ligand, FGFR1-3 receptors and downstream proteins, phospho PLCg1, total
PLCg1, phospho PLCg2, total PLCg2, phospho AKT and phospho ERK were seen in resistant
cells.
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activation and examined FGF2 expression by western blotting and ELISA (Figure 3.7A-B).
We observed complete abrogation of ERK activation in parental and resistant cells within
6hrs of inhibitor treatment and a signicant decrease in FGF2 expression. These results
suggest that increased activation of ERK in the resistant cells regulates increased expression
of FGF2.
3.3.6 Upregulated angiogenesis genes regulate increased pERK and FGF2 in
resistant tumors
Based on the above nding, we investigated other upregulated genes in the microarray
that were known to activate ERK. Using the IPA tool, we generated a functional gene-
interaction network, and found high J5 score-bearing dierentially expressed genes FZD4,
PLCg2, CX3CL1, CCL5, and FGFR3 as known activators of ERK (Figure 3.8). We hypoth-
esized that in the resistant cells these upregulated genes lead to increased activation of ERK
and subsequent increase in FGF2 expression. To test this, we rst validated overexpression
of these upstream genes in the resistant cells (Figure 3.9A-B). We then used siRNA ap-
proach to downregulate FZD4, PLCg2, CX3CL1, and CCL5 in both parental (Figure 3.10)
and resistant (Figure 3.11) cells and examined the eect on pERK and FGF2 expression.
We observed that downregulation of these genes resulted in a signicant decrease in ERK
activation and a corresponding decrease in FGF2 expression. Although this mechanism of
FGF2 regulation is common to both parental and resistant cells, it appears to be amplied
in the resistant cells due to overexpression of these upstream genes.
3.3.7 Co-targeting VEGF and FGFR sensitizes HNSCC tumors to bevacizumab
To test the contribution of FGF signaling in bevacizumab-associated acquired resistance,
we inhibited FGFRs in the resistant xenografts using PD173074 small molecule inhibitor
in combination with bevacizumab (Figure 3.12). Treatment with FGFR inhibitor alone
resulted in a modest decrease in tumor growth. However, cotargeting VEGF and FGFR
completely abrogated tumor growth in these resistant xenografts. Further, CD31 staining
in the tumor sections revealed a signicant decrease in MVD in the combination group
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(A) (B)
Figure 3.7: Increased ERK activation upregulates FGF2 expression in resistant cells.
Parental and resistant cells were treated with the MEK inhibitor U0126 to block ERK activation
and FGF2 expression was examined by western blotting (A) and ELISA (B). Complete abrogation
of ERK activation was observed within 6hrs of inhibitor treatment and a signicant decrease in
FGF2 expression.
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Figure 3.8: Upstream regulators of increased FGF2 expression in resistant tumors.
Using IPA tool, we identied potential activators of FGF2 based on at least one literature reference.
These included angiogenesis-related genes with high J5 scores such as FDZ4, PLC-g2, CX3CL1,
CCL5, and FGFR3, which were found to be upregulated in the resistant tumors using microarray
analysis. Majority of these proteins activate ERK, which is a known activator of FGF2.
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(A) (B)
Figure 3.9: Increased expression of angiogenesis genes FZD4, PLCg2, CX3CL1 and
CCL5 in resistant cells. (A), Western blot analysis conrmed increased protein levels of FZD4,
PLCg2 and CX3CL1 in tumor cells expanded from bevacizumab-treated resistant xenografts com-
pared to the parental Tu138 cell line. (B), Increased expression of CCL5 observed in resistant cells
using ELISA.
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(A) (B) (C)
(D) (E)
Figure 3.10: Angiogenesis genes induce pERK-mediated FGF2 expression in parental
cells. We used siRNA approach to downregulate FZD4 (A), PLCg2 (B), CX3CL1 (C), and CCL5
(E) in parental cells and examined the eect on pERK and FGF2 expression. We observed that
downregulation of these genes resulted in a signicant decrease in ERK activation and a correspond-
ing decrease in FGF2 expression. (D), siRNA-mediated knockdown of CCL5 protein in parental
cells as measured by ELISA.
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(D) (E)
Figure 3.11: Increased expression of angiogenesis genes leads to increased pERK and
FGF2 in resistant cells. We used siRNA approach to downregulate FZD4 (A), PLCg2 (B),
CX3CL1 (C), and CCL5 (E) in resistant cells and examined the eect on pERK and FGF2 expres-
sion. We observed that downregulation of these genes resulted in a signicant decrease in ERK
activation and a corresponding decrease in FGF2 expression. (D), siRNA-mediated knockdown of
CCL5 protein in resistant cells as measured by ELISA.
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Figure 3.12: Co-targeting VEGF and FGFR sensitizes HNSCC tumors to beva-
cizumab. Resistant xenografts (n = 12) were randomized into four treatment groups receiving
saline, single agent bevacizumab/ PD173074 or a combination. Bevacizumab and PD173074 were
administered intraperitoneally at 8mg/kg and 25mg/kg respectively. Tumor growth was assessed
for two weeks. (?) P = 0:0427; combination vs. bevacizumab alone.
compared to bevacizumab alone (Figure 3.13A-B). These data suggest that co-targeting
VEGF and FGFR sensitize resistant tumors to bevacizumab by disrupting angiogenesis.
3.4 CONCLUSIONS AND DISCUSSION
In recent years, there have been an increasing number of reports that described potential
mechanisms of resistance to antiangiogenic therapy. These studies indicate that tumors can
rely on multiple mechanisms of resistance using a variety of angiogenic proteins secreted by
both tumor cells and stromal cells. Hence, selection of one critical mediator of resistance for
cotargeting with VEGF remains a daunting task. To address this issue, preclinical models
that test combinatorial therapies along with VEGF inhibitors are needed to assist selection
of a suitable cotarget. Also, studies that elucidate the mechanisms of upregulation of these
resistance-contributing proteins will enable identication of functional networks that inte-
grate additional upstream genes as potential contributors of resistance.
66
(A)
(B)
Figure 3.13: Co-targeting VEGF and FGFR disrupted vasculature in resistant
xenografts. (A-B) CD31 staining in resistant xenografts showed signicantly reduced microvessel
density in the combination group (bevacizumab, PD173074) compared to bevacizumab alone.
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In the present study, we established a novel HNSCC xenograft model of acquired re-
sistance to bevacizumab and identied upregulation of FGF signaling in resistant tumors.
Increased expression of FGF2 was regulated by upstream genes including PLCg2, FZD4,
CX3CL1, and CCL5 via increased ERK signaling. We also showed that modulation of FGF
signaling in the resistant xenografts regulated sensitivity to bevacizumab.
FGFs are known to play an important role in a variety of cellular processes including
dierentiation, cell proliferation, apoptosis, angiogenesis and inammation [115{117]. These
FGF signaling-mediated functions can greatly contribute to to the process of tumorigenesis.
Accumulating evidence highlights the deregulation of FGF/FGFRs in cancer through dif-
ferent mechanisms, including aberrant expression, mutations, and gene amplications [118].
There are 4 known FGFRs, FGFR1 through FGFR4. These receptors dier in the distri-
bution patterns of specic isoforms on tumor cells and stromal cells, collectively mediating
autocrine and paracrine signaling in tumors. Studies have shown that FGF2/FGFRs au-
tocrine signaling contributes to EGFR TKI resistance in NSCLC lines [119,120].
In our HNSCC xenograft model of acquired resistance to bevacizumab, we have shown
upregulation of FGF signaling specically in the tumors cells. Several members of the FGF
pathway were found to be overexpressed including FGF2 ligand, FGFR1 through FGFR3
receptors, downstream proteins phospho PLCg1, PLCg1, phospho PCLg2, PLCg2, phospho
AKT and phospho ERK. This suggests that upregulation FGF/FGFR autocrine signaling
is one of the ways by which bevacizumab-resistant tumors cells bypass VEGF inhibition.
However, along with the aggressive growth phenotype of these resistant xenografts, these
tumors also display increased vasculature and reduced endothelial cell death. This clearly
indicates the existence of paracrine signaling between tumor cell-secreted FGF ligands and
endothelial cell-surface FGFRs. Although we have not analyzed the levels of FGFRs on the
endothelial cells, a recent report by Cascone et. al. [76], described upregulation of stromal
FGFR in a NSCLC xenograft model of acquired resistance to bevacizumab. FGF2 could
also induce production of several other angiogenic factors downstream to FGF signaling in
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both tumor cells and stromal cells, indirectly contributing to resistance.
We also demonstrated phospho ERK-mediated regulation of FGF expression in parental
cells and bevacizumab-resistant cells. Since, there is increased expression of phospho ERK
in the resistant cells, this can be one of the mechanisms by which the resistant cells increase
FGF2 expression. Based on this nding, we investigated other upregulated genes in the
microarray that were known to activate ERK. Using the IPA tool we selected high J5 score
bearing dierentially expressed genes including FZD4, PLCg2, CX3CL1 and CCL5 as known
activators of ERK. Downregulation of these upstream genes, in both parental and resistant
cells resulted in a decrease in activation of ERK and a corresponding decrease in FGF2 levels.
Although this mechanism is common to both parental and resistant cells, the overexpression
of upstream genes in resistant cells provides indirect evidence for increased FGF2 expression.
These results put forward an important concept in the phenomenon of acquired resis-
tance. In response to anti-VEGF therapy, our HNSCC tumors showed an increased expres-
sion of a number of tumorigenesis and angiogenesis-related genes. From literature, we know
that ERK is an integral growth-promoting protein, which is common to a wide variety of
growth-factor signaling pathways. Hence, increased activation of ERK could serve as a de-
fault mechanism of resistance that the tumors acquire to sustain growth and survival. Also,
FGF upregulation by the tumors will be a byproduct of increased ERK activation.
There is growing evidence that suggests upregulation of FGF/ FGFR axis in response
to anti-VEGF therapy [72, 76, 77, 121, 122]. Recent studies in mouse models of pancreatic
tumors and renal cell carcinoma have shown that dual inhibition of VEGFR and FGFR
can overcome anti-VEGF therapy resistance [123, 124]. However, there are no reports that
describe the mechanisms underlying FGF/ FGFR upregulation, in response to VEGF in-
hibitors.
Our results indicate that bevacizumab-refractory HNSCC tumors utilize FGF signaling
as a path of least resistance using a battery of proangiogenic genes that converge on ERK
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signaling to upregulate its expression and mediate resistance to anti-VEGF therapy. Knowl-
edge of these regulatory networks provide a stronger mechanistic rationale for co-targeting
VEGF and FGFR in future clinical trials.
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4.0 DISCUSSION
HNSCC is the eighth most common malignancy worldwide [1]. Currently, the average ve-
year survival rate for this disease is 62%. This rate is highly dependent on the stage at
diagnosis; with early stage diagnoses having an 82% ve-year survival rate and advanced
stages having only a 35% survival rate [2]. Despite advances in surgery and other treatment
modalities that enhance quality of life, survival rates have not improved signicantly in the
past fty years. This underscores the need for development of new therapeutic strategies in
HNSCC.
Antiangiogenic therapy represents a new promising anticancer therapeutic strategy. How-
ever, clinical trials with VEGF-targeted agents (such as bevacizumab) in HNSCC [55,56,81]
and several other cancers [109{111] indicate that the therapeutic ecacy of these drugs is
limited to date. Majority of the patients treated with these drugs demonstrate an initial
clinical response but eventually experience tumor re-growth. In addition, a subset of patients
exhibit inherent resistance to angiogenesis inhibition. These incomplete drug responses sug-
gest the presence of alternative signaling pathways that are active in the setting of VEGF
blockade. Currently, there are no studies that elucidate these molecular mechanisms of re-
sistance to anti-VEGF therapy in HNSCC. An understanding of these parallel pathways is
needed for the design of more eective antiangiogenic therapies for treatment of HNSCC.
Several potential mechanisms have been proposed in other cancers to account for the re-
sistance of tumors to antiangiogenic therapy [33,63{66]. These studies indicate that tumors
can rely on multiple escape mechanisms using a variety of angiogenic proteins secreted by
both tumor cells and stromal cells. In conjunction, there is a growing realization that each
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patient's tumor carries a unique molecular prole, demanding a personalized cancer treat-
ment plan. This demand is coupled with the need to identify which subsets of patients have
the best chance of benet. Clinical specimens including tumor tissue and patient sera can
serve as valuable resources to investigate the expression of potential biomarkers. However,
there are limitations to procuring high quality specimens in large numbers for a conclusive
analysis. More importantly, such analyses can only show an association between altered
proteins and resistance to anti-VEGF therapy, but not causation or an actual resistance
mechanism. Therefore, relevant preclinical models are indispensable for characterizing these
escape mechanisms. Animal models that test combinatorial therapies along with VEGF in-
hibitors are needed for selection of suitable cotargets.
In this dissertation, we established preclinical models of intrinsic and acquired resistance
to anti-VEGF antibody bevacizumab and identied potential biomarkers of drug response.
4.1 MECHANISMS OF INTRINSIC RESISTANCE IN HNSCC
We initiated these studies by screening a panel of HNSCC cell lines in vivo to examine their
dierential response to bevacizumab treatment. The HNSCC cell lines that displayed low
sensitivity to bevacizumab served as a model of intrinsic resistance and the cell lines that
showed high sensitivity to bevacizumab were used as a non-isogenic model for comparison.
Clinical trials of the VEGF-pathway inhibitors indicate that a minority of patients fail
to show even transitory clinical benet [55,56,81]. One potential mechanism for this innate
resistance might be the pre-existing multiplicity of redundant angiogenic factors. HNSCC
cells are known to produce a plethora of angiogenic factors that might allow continued an-
giogenesis in the setting of bevacizumab therapy. Therefore, we assayed for dierences in
secreted angiogenic factors between the bevacizumab-sensitive and -resistant HNSCC cell
lines using antibody array. We found higher expression of proangiogenic factors including
IL-8, IL-1, VEGF, FGF-a and TNF- in the resistant cells compared to the sensitive cells.
72
Among these cytokines, IL-8 was the most dierentially expressed protein in the resistant
cells. Based on this in vitro data, we formulated the hypothesis that IL8 contributes to beva-
cizumab resistance in the HNSCC xenograft models. We then tested this hypothesis in vivo
using shRNA-mediated knockdown of IL8 in resistant models and conversely overexpressing
IL8 in sensitive models and showed that IL8 can modulate response to bevacizumab in these
preclinical models.
In addition to identifying IL-8 as a mediator of bevacizumab resistance, we also examined
signaling pathways upstream to IL-8 that regulated high expression levels of IL-8 in the re-
sistant cells. It has been reported that SCC61 cells (bevacizumab-resistant) contain a PI3K
activating mutation (E542K) in Exon 9 [87]. Our data suggests that constitutive activation
of PI3K signaling in the bevacizumab-resistant SCC61 cells could serve as an escape mech-
anism to anti-VEGF therapy by regulating increased production of IL-8. PI3K signaling is
one of the most commonly activated pathways in several cancer types including HNSCC.
Our studies provide an added rationale for the use of PI3K inhibitors to overcome resistance
to antiangiogenic agents such as bevacizumab. Also, PI3K inhibitors such as BYL719 and
PX-866 are currently in phase I/ II clinical trials for recurrent/ metastatic HNSCC, NSCLC
and CRC.
We also demonstrated IL-1 as a mechanism of IL-8 regulation in the resistant cells.
Studies have shown that tumor cells upregulate IL-1 to promote angiogenesis, tumor growth
and metastasis. Also, in our antibody array analysis, we have shown that the resistant cells
express increased levels of IL-1 along with IL-8 and several other proangiogenic proteins.
Our ndings suggest that increased expression of IL-1 in the resistant cells contributes to
increased IL-8 production, which mediates bevacizumab resistance. Hence, increased IL-1
signaling could be another potential mechanism of resistance to anti-VEGF therapy in HN-
SCC. Anti-IL1 monoclonal antibodies such as anakinra, which have shown clinical benet
in patients with rheumatoid arthritis, might also enhance antiangiogenic therapeutic ecacy.
As our data identied IL-8 as a mediator of bevacizumab resistance in preclinical HNSCC
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xenograft models, we also assessed IL-8 levels in sera from HNSCC patients who received
bevacizumab as a part of their treatment regimen. Serum analysis suggested an inverse cor-
relation between IL-8 levels with clinical outcome. Future clinical trials with angioangiogenic
agents that assess IL-8 levels in patients will further validate the use of IL-8 as a relevant
biomarker of treatment response or resistance.
In the light of these preclinical and clinical ndings, we foresee IL-8 to be an impor-
tant player in governing sensitivity to antiangiogenic therapy. Several IL-8 targeting agents
are currently in clinical development primarily for the treatment of inammatory diseases
and these agents have shown antitumor and antiangiogenic activity in preclinical mod-
els [105,106].
Our data suggests that the concurrent use of anti-VEGF agents such as bevacizumab
and IL-8 targeting agents may help overcome resistance and improve therapeutic ecacy of
antiangiogenic therapy in HNSCC.
4.2 MECHANISMS OF ACQUIRED RESISTANCE IN HNSCC
In this body of work, we generated a novel HNSCC xenograft model of acquired resistance
to bevacizumab and identied FGF as an escape mechanism to anti-VEGF therapy. In order
to establish the xenograft model, we used an incremental drug dosing regime. Mice were
treated with bevacizumab at an initial dose of 4mg/kg followed by increasing the dose by
4mg/kg with every subsequent increase in tumor volume. Although use of this incremen-
tal dosing regime is not representative of clinical therapy, we employed this approach to
eliminate the sensitive tumor cells and sequentially selected for the resistant clones. After
prolonged therapy, we observed a signicant dierence in the tumor growth between the
chronically treated HNSCC xenografts (less sensitive) and the isogenic parental (more sen-
sitive) xenografts. This isogenic nature of the sensitive and resistant tumors is a signicant
advantage of this model, as it enables ideal comparison within the isogenic pair overcoming
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the genetic and phenotypic variation across dierent cell lines. We further characterized the
preclinical model by assessing microvessel density and endothelial cell apoptosis and found
that the bevacizumab-resistant phenotype is associated with revascularization of these tu-
mors and reduced endothelial cell death.
After successful generation of the preclinical model, we next wanted to identify the
molecular changes initiated by tumor cells to mediate bevacizumab resistance. In order to
do so, we performed whole genome microarray analysis on the isogenic pair of becaizumab-
sensitive and -resistant tumors. We found 150 genes that were upregulated and 31 genes
that were downregulated in the resistant tumors. Among the angiogenesis-related genes, we
found upregulation of FGF2, FGFR3, PLCg2, FZD4, CX3CL1, and CCL5 in the resistant
tumors. Functional interaction network involving DE genes identied FGF2 as a highly
connected nodal gene with upregulated proangiogenic genes FGFR3, PLCg2, CASP1 and
BGN. Interestingly, three of these genes FGF2, FGFR3 and PLCg2 belong to the FGF sig-
naling pathway. These results led us to hypothesize that the FGF axis may be involved in
bevacizumab-associated acquired resistance in our HNSCC xenograft model.
FGFs are known to play an important role in a variety of cellular processes includ-
ing dierentiation, cell proliferation, apoptosis, angiogenesis and inammation. These FGF
signaling-mediated functions can greatly contribute to the process of tumorigenesis. Accu-
mulating evidence highlights the deregulation of FGF/FGFRs in cancer through dierent
mechanisms, including aberrant expression, mutations, and gene amplications. There are 4
known FGFRs, FGFR1 through FGFR4. These receptors dier in the distribution patterns
of specic isoforms on tumor cells and stromal cells, collectively mediating autocrine and
paracrine signaling in tumors. Studies have shown that FGF2/FGFRs autocrine signaling
contributes to EGFR-TKI resistance in NSCLC lines.
We also addressed the molecular basis for overexpression of FGF2 in the resistant tumors
and observed that the resistant cells had higher levels of phospho ERK and that the expres-
sion of FGF2 was dependent in part to ERK activity in both parental and resistant cells.
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Using the IPA tool we then found several high J5 score bearing DE genes including FZD4,
PLCg2, CX3CL1 and CCL5 which are well-known activators of ERK. Downregulation of
these upstream genes, in both parental and resistant cells resulted in a decrease in activation
of ERK and a corresponding decrease in FGF2 levels. Although this mechanism of FGF2
regulation was common to both parental and resistant cells, it appears to be amplied in
the resistant cells due to overexpression of these upstream genes.
In response to anti-VEGF therapy, our HNSCC tumors showed an increased expression
of a number of tumorigenesis and angiogenesis-related genes. Despite the changes in the
expression of many dierent cytokines, the cumulative eects of these changes appears to
feed through a common protein or pathway to exert its eect. In our acquired model, the
overexpression of FZD4, PLCg2, CX3CL1, and CCL5 has the common eect of ERK acti-
vation which eventually lead to the overexpression of FGF2. Based on this observation, we
can put forth a hypothesis that although the treatment with antiangiogenic agents leads to
pleiotrophic changes to the tumor, therapeutic attempts to reverse the resistance may not
require the inhibition of all these dierentially expressed cytokines but rather one or two
pathways that these changes mainly feeds through. In our model, that common pathway
appeared to be ERK and eventually FGF2. These data also provide an added rationale for
use of ERK inhibitors in conjunction with bevacizumab as a means to overcome resistance
to anti-VEGF therapy. A multicenter phase I trial of the ERK Inhibitor BAY 86-9766 in
patients with advanced cancer indicated some evidence of clinical benet across a range of
tumor types [125], an encouraging trend for future clinical trials.
Since IL-8 was the primary mechanism of bevacizumab resistance in the intrinsic mod-
els, we also assessed IL-8 levels in our model of a acquired resistance. Interestingly, IL-8
was downregulated in the acquired resistant tumors, suggesting that the tumors excluded
this mechanism to maintain angiogenesis and sustain tumor growth in presence of VEGF
blockade. These ndings indicate that there might be an inherent dierence in the under-
lying mechanisms of intrinsic and acquired resistance to antiangiogenic therapies. These
distinct mechanisms could correspond to dierent patient subpopulations. Identication of
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these subsets can help improve pretreatment patient selection for personalized medicine and
enhance the therapeutic ecacy of antiangiogenic therapies.
4.3 CONCLUDING REMARKS
Our work has generated preclinical HNSCC models of intrinsic and acquired resistance to
anti-VEGF antibody bevacizumab. These models serve as a valuable resource to test novel
combinatorial therapies with VEGF inhibitors. In these xenograft models, we identied
two distinct molecular mechanisms of resistance to bevacizumab. IL-8 signaling mediated
intrinsic resistance while upregulation of FGF signaling in response to anti-VEGF therapy
contributed to acquired resistance. Although, IL-8 and FGF have been previously impli-
cated in anti-VEGF therapy resistance in other cancers, our study is the rst to validate
these mechanisms in HNSCC.
The most novel nding of our work is the identication of regulatory mechanisms that
result in upregulation of IL-8 and FGF in our resistant models. We believe that knowledge
of these regulatory mechanisms is necessary to discover functional networks that integrate
additional upstream genes as potential contributors of resistance. We identied PI3K and
IL-1 signaling as positive regulators of IL-8 expression, indirectly contributing to intrinsic
resistance. In the model of acquired resistance, we identied a proangiogenic signature
including FZD4, PLCg2, CX3CL1, and CCL5 genes that mediated upregulation of FGF via
increased ERK signaling. Above ndings provide a mechanistic rationale for for co-targeting
VEGF together with the elements of these evasive mechanisms such as IL-8 and FGF to
enhance the therapeutic ecacy of antiangiogenic therapy.
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APPENDIX
MICROARRAY DATA
Table A1: List of 181 dierentially expressed genes in bevacizumab-resistant tumors.
Rank Description J5-score Accession #
1 hemoglobin, beta (HBB) 27.473 NM 000518.4
2 insulin-like growth factor binding protein 6 (IGFBP6) 27.04 NM 002178.2
3 H19, imprinted maternally expressed transcript (non-
protein coding) (H19), non-coding RNA.
25.785 NR 002196.1
4 alkaline phosphatase, liver/bone/kidney (ALPL), tran-
script variant 1
22.435 NM 000478.2
5 retinoic acid receptor responder (tazarotene induced) 3
(RARRES3)
21.255 NM 004585.2
6 hect domain and RLD 5 (HERC5) 19.807 NM 016323.1
7 keratin 10 (epidermolytic hyperkeratosis; keratosis pal-
maris et plantaris) (KRT10)
18.764 NM 000421.2
8 frizzled homolog 4 (Drosophila) (FZD4) 18.239 NM 012193.2
9 NADH dehydrogenase (ubiquinone) 1 alpha subcom-
plex, 4-like 2 (NDUFA4L2)
17.73 NM 020142.3
10 absent in melanoma 2 (AIM2) 17.325 NM 004833.1
11 lymphocyte antigen 6 complex, locus E (LY6E) 16.749 NM 002346.1
12 ISG15 ubiquitin-like modier (ISG15) 16.646 NM 005101.1
13 Sp8 transcription factor (SP8), transcript variant 2 16.322 NM 198956.1
Continued on next page
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14 interferon-induced protein with tetratricopeptide re-
peats 2 (IFIT2)
16.015 NM 001547.3
15 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60
(DDX60)
15.934 NM 017631.3
16 interferon-induced protein 44 (IFI44) 15.841 NM 006417.2
17 epithelial stromal interaction 1 (breast) (EPSTI1),
transcript variant 2
14.501 NM 033255.2
18 interferon-induced protein with tetratricopeptide re-
peats 1 (IFIT1), transcript variant 2
14.27 NM 001548.2
19 mal, T-cell dierentiation protein 2 (MAL2) 13.948 NM 052886.1
20 chemokine (C-X3-C motif) ligand 1 (CX3CL1) 13.329 NM 002996.3
21 PRED: similar to epiplakin 1 (LOC648526) 13.171 XM 937579.1
22 chemokine (C-X-C motif) receptor 7 (CXCR7) 13.142 NM 020311.1
23 MSTP131 (MST131) mRNA, complete cds 13.023 Hs.551128
24 phospholipase C, gamma 2 (phosphatidylinositol-
specic) (PLCG2)
12.871 NM 002661.1
25 hect domain and RLD 6 (HERC6), transcript variant 1 12.702 NM 001013005.1
26 interferon, alpha-inducible protein 27 (IFI27), tran-
script variant 2
12.238 NM 005532.3
27 biglycan (BGN) 12.165 NM 001711.3
28 interferon-induced protein with tetratricopeptide re-
peats 3 (IFIT3)
12.135 NM 001031683.1
29 HLA complex P5 (HCP5) 12.074 NM 006674.2
30 interferon-induced protein 44-like (IFI44L) 12.059 NM 006820.1
31 major histocompatibility complex, class I, B (HLA-B) 11.901 NM 005514.5
32 major histocompatibility complex, class I, H (pseudo-
gene) (HLA-H), non-coding RNA.
11.736 NR 001434.1
33 interleukin 20 receptor beta (IL20RB) 11.685 NM 144717.2
34 interferon stimulated exonuclease gene 20kDa (ISG20) 11.617 NM 002201.4
35 sterile alpha motif domain containing 9 (SAMD9) 11.609 NM 017654.2
36 phosducin-like 3 (PDCL3) 11.58 XM 929879.1
37 XIAP associated factor 1 (XAF1), transcript variant 2 11.535 NM 199139.1
Continued on next page
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38 growth factor receptor-bound protein 10 (GRB10),
transcript variant 1
11.518 NM 005311.3
39 neuromedin U (NMU) 11.506 NM 006681.1
40 prostaglandin E receptor 4 (subtype EP4) (PTGER4) 11.382 NM 000958.2
41 cellular retinoic acid binding protein 2 (CRABP2) 11.227 NM 001878.2
42 histone cluster 1, H2bk (HIST1H2BK) 11.207 NM 080593.1
43 prostaglandin E synthase (PTGES) 11.144 NM 004878.3
44 protease, serine, 23 (PRSS23) 11.034 NM 007173.3
45 KH homology domain containing 1-like (KHDC1L) 11.014 NM 001126063.2
46 PRED: hypothetical gene supported by BC013438
(LOC375295)
10.953 XM 944366.1
47 transcobalamin I (vitamin B12 binding protein, R
binder family) (TCN1)
10.862 NM 001062.2
48 chemokine (C-C motif) ligand 5 (CCL5) 10.718 NM 002985.2
49 regulator of G-protein signalling 2, 24kDa (RGS2) 10.661 NM 002923.1
50 chromosome 5 open reading frame 15 (C5orf15) 10.617 NM 020199.1
51 carbonyl reductase 3 (CBR3) 10.615 NM 001236.3
52 2'-5'-oligoadenylate synthetase-like (OASL), transcript
variant 1
10.599 NM 003733.2
53 interferon induced transmembrane protein 3 (1-8U)
(IFITM3)
10.587 NM 021034.1
54 receptor (chemosensory) transporter protein 4 (RTP4) 10.558 NM 022147.2
55 Rho GDP dissociation inhibitor (GDI) beta
(ARHGDIB)
10.533 NM 001175.4
56 zinc nger CCCH-type, antiviral 1 (ZC3HAV1), tran-
script variant 2
10.333 NM 024625.3
57 sperm associated antigen 9 (SPAG9), transcript variant
2
10.261 NM 172345.1
58 interferon regulatory factor 1 (IRF1) 10.254 NM 002198.1
59 calmodulin-like 3 (CALML3) 10.191 NM 005185.2
60 STAM binding protein-like 1 (STAMBPL1) 10.182 NM 020799.2
61 Kruppel-like factor 4 (gut) (KLF4) 10.163 NM 004235.3
Continued on next page
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62 myxovirus (inuenza virus) resistance 1, interferon-
inducible protein p78 (mouse) (MX1)
10.12 NM 002462.2
63 cysteine and glycine-rich protein 2 (CSRP2) 10.062 NM 001321.1
64 PRED: similar to creatine kinase, mitochondrial 1B pre-
cursor (LOC649970)
9.97 XM 939056.1
65 transporter 1, ATP-binding cassette, sub-family B
(MDR/TAP) (TAP1)
9.969 NM 000593.5
66 desmocollin 1 (DSC1), transcript variant Dsc1b 9.939 NM 004948.2
67 transcription elongation factor A (SII)-like 8
(TCEAL8), transcript variant 1
9.883 NM 153333.2
68 Rho guanine exchange factor (GEF) 16 (ARHGEF16) 9.851 NM 014448.2
69 transmembrane protein 66 (TMEM66) 9.822 NM 016127.4
70 microtubule-associated protein, RP/EB family, memb
2 (MAPRE2)
9.817 NM 014268.1
71 interferon induced with helicase C domain 1 (IFIH1) 9.8 NM 022168.2
72 SAR1 gene homolog A (S. cerevisiae) (SAR1A) 9.779 NM 020150.3
73 broblast growth factor 2 (basic) (FGF2) 9.741 NM 002006.3
74 nephroblastoma overexpressed gene (NOV) 9.724 NM 002514.2
75 interferon induced transmembrane protein 2 (1-8D)
(IFITM2)
9.676 NM 006435.1
76 HD domain containing 2 (HDDC2) 9.647 NM 016063.1
77 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase,
polypeptide 5 (B4GALT5)
9.642 NM 004776.2
78 beta-2-microglobulin (B2M) 9.626 NM 004048.2
79 chloride channel, calcium activated, family memb 2
(CLCA2)
9.512 NM 006536.4
80 caspase 1, apoptosis-related cysteine peptidase (inter-
leukin 1, beta, convertase) (CASP1), transcript variant
alpha
9.477 NM 033292.2
81 prominin 2 (PROM2) 9.456 NM 144707.1
82 thioredoxin interacting protein (TXNIP) 9.372 NM 006472.1
Continued on next page
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83 small nucleolar RNA, C/D box 13 (SNORD13), small
nucleolar RNA.
9.329 Hs.583806
84 peptidase D (PEPD) 9.311 NM 000285.1
85 amyotrophic lateral sclerosis 2 (juvenile) chromosome
region, candidate 4 (ALS2CR4), transcript variant 1
9.26 NM 152388.1
86 2'-5'-oligoadenylate synthetase 2, 69/71kDa (OAS2),
transcript variant 2
9.257 NM 002535.2
87 histone cluster 1, H1c (HIST1H1C) 9.221 NM 005319.3
88 CDC42 eector protein (Rho GTPase binding) 4
(CDC42EP4)
9.207 NM 012121.4
89 hyaluronan-mediated motility receptor (RHAMM)
(HMMR), transcript variant 2
9.178 NM 012485.1
90 pyridoxamine 5'-phosphate oxidase (PNPO) 9.147 NM 018129.1
91 solute carrier family 9 (sodium/hydrogen exchanger),
memb 3 regulator 1 (SLC9A3R1)
9.117 NM 004252.1
92 vav 3 guanine nucleotide exchange factor (VAV3), tran-
script variant 1
9.094 NM 006113.4
93 leprecan-like 1 (LEPREL1) 9.091 NM 018192.2
94 major histocompatibility complex class I HLA-A29.1 9.044 NM 001080840.1
95 transmembrane protein 106C (TMEM106C) 9.029 NM 024056.2
96 LSM1 homolog, U6 small nuclear RNA associated (S.
cerevisiae) (LSM1)
8.899 NM 014462.1
97 coiled-coil domain containing 6 (CCDC6) 8.843 NM 005436.2
98 insulin receptor substrate 1 (IRS1) 8.817 NM 005544.1
99 ash2 (absent, small, or homeotic)-like (Drosophila)
(ASH2L)
8.767 NM 004674.1
100 tumor necrosis factor (ligand) superfamily, memb 10
(TNFSF10)
8.742 NM 003810.2
101 PRED: misc RNA (LOC729816), miscRNA. 8.74 XR 042352.1
102 cyclin D3 (CCND3) 8.728 NM 001760.2
103 major histocompatibility complex, class I, F (HLA-F),
transcript variant 1
8.705 NM 018950.1
Continued on next page
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104 major histocompatibility complex, class I, A (HLA-A) 8.68 NM 002116.5
105 NAD(P)H dehydrogenase, quinone 1 (NQO1), tran-
script variant 1
8.631 NM 000903.2
106 PDZ binding kinase (PBK) 8.594 NM 018492.2
107 PRED: similar to hCG1983233 (LOC100134304) 8.56 XM 001720739.1
108 Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2 (CITED2), transcript
variant 1
8.501 NM 006079.3
109 anillin, actin binding protein (ANLN) 8.5 NM 018685.2
110 heterogeneous nuclear ribonucleoprotein A1 pseudogene
(LOC728643), non-coding RNA.
8.472 NR 003277.1
111 PYD and CARD domain containing (PYCARD), tran-
script variant 1
8.469 NM 145183.1
112 proline synthetase co-transcribed homolog (bacterial)
(PROSC)
8.454 NM 007198.2
113 PRED: hypothetical protein LOC100130919
(LOC100130919)
8.448 XM 001722872.1
114 poly (ADP-ribose) polymerase family, memb 9
(PARP9)
8.448 NM 031458.1
115 enhancer of rudimentary homolog (Drosophila) (ERH) 8.447 NM 004450.1
116 neuregulin 4 (NRG4) 8.433 NM 138573.1
117 NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
10, 22kDa (NDUFB10)
8.433 NM 004548.1
118 broblast growth factor receptor 3 (achondroplasia,
thanatophoric dwarsm) (FGFR3), transcript variant
2
8.424 NM 000142.2
119 chromosome 10 open reading frame 99 (C10orf99) 8.405 NM 207373.1
120 minichromosome maintenance complex component 6
(MCM6)
8.352 NM 005915.4
121 calpain 1, (mu/I) large subunit (CAPN1) 8.316 NM 005186.2
122 tumor protein p73-like (TP73L) 8.262 NM 003722.3
123 carboxymethylenebutenolidase homolog (Pseu-
domonas) (CMBL)
8.202 NM 138809.2
Continued on next page
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124 asp (abnormal spindle) homolog, microcephaly associ-
ated (Drosophila) (ASPM)
8.189 NM 018136.2
125 tumor protein p63 (TP63), transcript variant 5 8.182 NM 001114981.1
126 PRED: similar to Nonhistone chromosomal protein
HMG-17 (High-mobility group nucleosome binding do-
main 2) (LOC148915)
8.181 XM 937758.1
127 leptin receptor overlapping transcript-like 1 (LEP-
ROTL1)
8.154 NM 015344.1
128 chromosome X open reading frame 26 (CXorf26) 8.143 NM 016500.3
129 exportin 1 (CRM1 homolog, yeast) (XPO1) 8.135 NM 003400.3
130 microsomal glutathione S-transferase 2 (MGST2) 8.128 NM 002413.3
131 general transcription factor IIE, polypeptide 2, beta
34kDa (GTF2E2)
8.122 NM 002095.3
132 defensin, beta 1 (DEFB1) 8.109 NM 005218.3
133 chromosome 6 open reading frame 173 (C6orf173) 8.103 NM 001012507.1
134 cyclin B2 (CCNB2) 8.092 NM 004701.2
135 complement factor D (adipsin) (CFD) 8.065 NM 001928.2
136 COBL-like 1 (COBLL1) 8.064 NM 014900.3
137 metallothionein 1E (functional) (MT1E) 8.057 NM 175617.2
138 glutathione reductase (GSR) 8.038 NM 000637.2
139 RNA, U1A3 small nuclear (RNU1A3), small nuclear
RNA.
-8.131 NR 004430.1
140 collagen, type V, alpha 2 (COL5A2) -8.2 NM 000393.2
141 late cornied envelope 3E (LCE3E) -8.245 NM 178435.2
142 small proline-rich protein 2C (pseudogene) (SPRR2C),
non-coding RNA.
-8.265 NR 003062.1
143 immediate early response 3 (IER3) -8.484 NM 052815.1
144 tribbles homolog 3 (Drosophila) (TRIB3) -8.591 NM 021158.3
145 serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), memb 2 (SERPINE2)
-8.669 NM 006216.2
146 small proline-rich protein 2B (SPRR2B) -9.017 NM 001017418.1
147 cathepsin L2 (CTSL2) -9.25 NM 001333.2
Continued on next page
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148 fatty acid binding protein 4, adipocyte (FABP4) -9.319 NM 001442.1
149 cornifelin (CNFN) -9.335 NM 032488.2
150 keratin 80 (KRT80), transcript variant 1 -9.359 NM 182507.2
151 RNA, U1 small nuclear 3 (RNU1-3), small nuclear
RNA.
-9.392 NR 004408.1
152 RNA, U1G2 small nuclear (RNU1G2), small nuclear
RNA.
-9.445 NR 004426.1
153 tripartite motif family-like 2 (TRIML2) -9.485 NM 173553.1
154 RNA, U1 small nuclear 5 (RNU1-5), small nuclear
RNA.
-9.488 NR 004400.1
155 protein phosphatase 1, regulatory (inhibitor) subunit
15A (PPP1R15A)
-9.518 NM 014330.2
156 secretory leukocyte peptidase inhibitor (SLPI) -9.607 NM 003064.2
157 colony stimulating factor 2 (granulocyte-macrophage)
(CSF2)
-9.845 NM 000758.2
158 heparin-binding EGF-like growth factor (HBEGF) -10.066 NM 001945.1
159 uridine phosphorylase 1 (UPP1), transcript variant 1 -10.249 NM 003364.2
160 PRED: family with sequence similarity 25, memb A
(FAM25A)
-10.852 XM 001723781.1
161 lipocalin 2 (LCN2) -10.964 NM 005564.2
162 PRED: similar to Ribosome biogenesis protein BMS1
homolog (LOC643150)
-11.046 XM 926523.1
163 PRED: hypothetical LOC643479 (LOC643479) -11.134 XM 926802.1
164 cysteine-rich C-terminal 1 (CRCT1) -11.457 NM 019060.1
165 ornithine decarboxylase 1 (ODC1) -11.953 NM 002539.1
166 hemoglobin, alpha 2 (HBA2) -12.011 NM 000517.3
167 interleukin 1 family, memb 9 (IL1F9) -12.163 NM 019618.2
168 cyclin A1 (CCNA1) -12.222 NM 003914.2
169 interleukin 8 (IL8) -12.319 NM 000584.2
170 matrix metallopeptidase 9 (gelatinase B, 92kDa gelati-
nase, 92kDa type IV collagenase) (MMP9)
-12.672 NM 004994.2
171 small proline-rich protein 2D (SPRR2D) -12.987 NM 006945.3
Continued on next page
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172 PRED: similar to Ribosome biogenesis protein BMS1
homolog (LOC647987)
-13.172 XM 937044.1
173 PRED: hypothetical LOC643161 (LOC643161) -14.229 XM 926530.1
174 small proline-rich protein 2E (SPRR2E) -14.686 NM 001024209.2
175 ribonuclease, RNase A family, 7 (RNASE7) -15.01 NM 032572.2
176 PRED: hypothetical protein LOC647993 (LOC647993) -15.078 XM 937048.1
177 small proline-rich protein 2A (SPRR2A) -16.539 NM 005988.2
178 small proline-rich protein 2F (SPRR2F) -16.568 NM 001014450.1
179 late cornied envelope 3D (LCE3D) -20.282 NM 032563.1
180 defensin, beta 103B (DEFB103B) -22.442 XM 928791.1
181 small proline-rich protein 2G (SPRR2G) -24.715 NM 001014291.1
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